Evofem Biosciences (EVFM) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - $ / shares	6 Months Ended
	Jun. 30, 2024	Aug. 08, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-36754
Entity Registrant Name	EVOFEM BIOSCIENCES, INC.
Entity Central Index Key	0001618835
Entity Tax Identification Number	20-8527075
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7770 Regents Road
Entity Address, Address Line Two	Suite 113-618
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92122
City Area Code	(858)
Local Phone Number	550-1900
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	EVFM
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		100,328,686
Entity Listing, Par Value Per Share	$ 0.0001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents
Restricted cash	692	580
Trade accounts receivable, net	4,617	5,738
Inventories	1,060	1,697
Prepaid and other current assets	845	1,195
Total current assets	7,214	9,210
Property and equipment, net	1,187	1,203
Operating lease right-of-use assets	114	106
Other noncurrent assets	36	35
Total assets	8,551	10,554
Current liabilities:
Accounts payable	16,033	17,020
Short-term debt (Note 4)	397
Accrued expenses	4,752	4,227
Accrued compensation	3,280	2,609
Operating lease liabilities-current	113	97
Derivative liabilities	942	1,926
Other current liabilities	3,776	3,316
Other current liabilities – related party	1,000
Total current liabilities	73,178	72,463
Operating lease liabilities- noncurrent	1	8
Total liabilities	73,179	72,471
Commitments and contingencies (Note 7)
Convertible and redeemable preferred stock, $0.0001 par value, Senior to common stock
Series E-1 and F-1 convertible preferred stock, 2,300 and 95,000 shares authorized; 1,968 and 1,874 shares of E-1 issued and outstanding as of June 30, 2024 and December 31, 2023, respectively; 22,280 shares of F-1 issued and outstanding at each of June 30, 2024 and December 31, 2023	4,687	4,593
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2024 and December 31, 2023
Common Stock, $0.0001 par value; 3,000,000,000 shares authorized; 82,828,686 and 20,007,799 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	8	2
Additional paid-in capital	823,709	823,036
Accumulated other comprehensive loss	(781)	(849)
Accumulated deficit	(892,251)	(888,699)
Total stockholders’ deficit	(69,315)	(66,510)
Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit	8,551	10,554
Baker Bros. Notes [Member]
Current liabilities:
Convertible notes	13,239	14,731
Adjuvant Notes [Member]
Current liabilities:
Convertible notes	$ 29,646	$ 28,537

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	82,828,686	20,007,799
Common stock, shares outstanding	82,828,686	20,007,799
Series E-1 Convertible and Redeemable Preferred Stock [Member]
Convertible preferred stock, shares authorized	2,300	2,300
Convertible preferred stock, shares issued	1,968	1,874
Convertible preferred stock, shares outstanding	1,968	1,874
Series F-1 Convertible and Redeemable Preferred Stock [Member]
Convertible preferred stock, shares authorized	95,000	95,000
Convertible preferred stock, shares issued	22,280	22,280
Convertible preferred stock, shares outstanding	22,280	22,280

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Product sales, net	$ 4,160	$ 2,458	$ 7,763	$ 8,267
Operating Expenses:
Cost of goods sold	769	2,293	1,453	3,669
Research and development	270	402	864	942
Selling and marketing	2,243	2,197	4,588	6,051
General and administrative	2,267	4,902	5,091	8,520
Total operating expenses	5,549	9,794	11,996	19,182
Loss from operations	(1,389)	(7,336)	(4,233)	(10,915)
Other income (expense):
Interest income	6	8	10	26
Other expense, net	(558)	(1,127)	(1,174)	(1,445)
Loss on issuance of financial instruments	(25)	(27)	(3,300)	(111)
Gain on debt extinguishment			1,120
Change in fair value of financial instruments	3,325	(73)	4,127	1,539
Total other income (expense), net	2,748	(1,219)	783	9
Income (loss) before income tax	1,359	(8,555)	(3,450)	(10,906)
Income tax expense	(8)	(3)	(8)	(6)
Net income (loss)	1,351	(8,558)	(3,458)	(10,912)
Convertible preferred stock deemed dividends	(47)		(94)
Net income (loss) attributable to common stockholders	$ 1,304	$ (8,558)	$ (3,552)	$ (10,912)
Net income (loss) per share attributable to common stockholders:
Basic (Note 2)	$ 0.02	$ (5.43)	$ (0.07)	$ (6.60)
Diluted (Note 2)	$ 0	$ (5.43)	$ (0.07)	$ (6.60)
Weighted-average shares used to compute net income (loss) per share attributable to common shareholders:
Basic	66,773,313	1,576,158	48,983,853	1,654,026
Diluted	1,613,722,212	1,576,158	48,983,853	1,654,026

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net income (loss)	$ 1,351	$ (8,558)	$ (3,458)	$ (10,912)
Other comprehensive income:
Change in fair value of financial instruments attributed to credit risk change (Note 4)	(256)	8,368	68	23,828
Comprehensive income (loss)	$ 1,095	$ (190)	$ (3,390)	$ 12,916

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Convertible and Redeemable Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Series E-1 Convertible and Redeemable Preferred Stock [Member] Preferred Stock [Member]	Series E-1 Convertible and Redeemable Preferred Stock [Member]	Series F-1 Convertible and Redeemable Preferred Stock [Member] Preferred Stock [Member]	Series F-1 Convertible and Redeemable Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022						$ 817,367	$ 49,527	$ (938,694)	$ (71,800)
Common stock, Balance, shares at Dec. 31, 2022					984,786
Issuance of common stock upon cash exercise of warrants						67			67
Issuance of common stock upon cash exercise of warrants, shares					24,200
Issuance of common stock upon noncash exercise of Purchase Rights						180			180
Issuance of common stock upon noncash exercise of Purchase Rights, shares					718,704
Stock-based compensation						417			417
Change in fair value of financial instruments attributed to credit risk change (Note 4)							15,460		15,460
Net income (loss)								(2,354)	(2,354)
Issuance of SSNs (Note 4)						1,629			1,629
Balance at Mar. 31, 2023						819,660	64,987	(941,048)	(56,401)
Common stock, Balance, shares at Mar. 31, 2023					1,727,690
Balance at Dec. 31, 2022						817,367	49,527	(938,694)	(71,800)
Common stock, Balance, shares at Dec. 31, 2022					984,786
Change in fair value of financial instruments attributed to credit risk change (Note 4)									23,828
Net income (loss)									(10,912)
Balance at Jun. 30, 2023						820,587	73,355	(949,606)	(55,664)
Common stock, Balance, shares at Jun. 30, 2023					2,524,239
Balance at Mar. 31, 2023						819,660	64,987	(941,048)	(56,401)
Common stock, Balance, shares at Mar. 31, 2023					1,727,690
Issuance of common stock upon cash exercise of warrants						101			101
Issuance of common stock upon cash exercise of warrants, shares					122,729
Issuance of common stock upon noncash exercise of Purchase Rights						6			6
Issuance of common stock upon noncash exercise of Purchase Rights, shares					673,820
Stock-based compensation						268			268
Change in fair value of financial instruments attributed to credit risk change (Note 4)							8,368		8,368
Net income (loss)								(8,558)	(8,558)
Issuance of SSNs (Note 4)						499			499
Noncash reclassification of liability-classified derivatives to equity						53			53
Balance at Jun. 30, 2023						820,587	73,355	(949,606)	(55,664)
Common stock, Balance, shares at Jun. 30, 2023					2,524,239
Balance at Dec. 31, 2023	$ 1,874		$ 2,719		$ 2	823,036	(849)	(888,699)	$ (66,510)
Temporary equity, Balance, shares at Dec. 31, 2023	1,874	1,874	22,280	22,280
Common stock, Balance, shares at Dec. 31, 2023					20,007,799				20,007,799
Issuance of common stock upon cash exercise of warrants						15			$ 15
Issuance of common stock upon cash exercise of warrants, shares					246,153
Issuance of common stock upon noncash exercise of Purchase Rights					$ 2	87			89
Issuance of common stock upon noncash exercise of Purchase Rights, shares					17,725,000
Issuance of common stock upon conversion of notes					$ 1	34			35
Issuance of common stock upon conversion of notes, shares					10,731,443
Stock-based compensation						237			237
Change in fair value of financial instruments attributed to credit risk change (Note 4)							324		324
Series E-1 Shares dividends	$ 47							(47)	(47)
Series E-1 Shares dividends, shares	47
Net income (loss)								(4,809)	(4,809)
Balance at Mar. 31, 2024	$ 1,921		$ 2,719		$ 5	823,409	(525)	(893,555)	(70,666)
Temporary equity, Balance, shares at Mar. 31, 2024	1,921		22,280
Common stock, Balance, shares at Mar. 31, 2024					48,710,395
Balance at Dec. 31, 2023	$ 1,874		$ 2,719		$ 2	823,036	(849)	(888,699)	$ (66,510)
Temporary equity, Balance, shares at Dec. 31, 2023	1,874	1,874	22,280	22,280
Common stock, Balance, shares at Dec. 31, 2023					20,007,799				20,007,799
Change in fair value of financial instruments attributed to credit risk change (Note 4)									$ 68
Net income (loss)									(3,458)
Balance at Jun. 30, 2024	$ 1,968		$ 2,719		$ 8	823,709	(781)	(892,251)	$ (69,315)
Temporary equity, Balance, shares at Jun. 30, 2024	1,968	1,968	22,280	22,280
Common stock, Balance, shares at Jun. 30, 2024					82,828,686				82,828,686
Balance at Mar. 31, 2024	$ 1,921		$ 2,719		$ 5	823,409	(525)	(893,555)	$ (70,666)
Temporary equity, Balance, shares at Mar. 31, 2024	1,921		22,280
Common stock, Balance, shares at Mar. 31, 2024					48,710,395
Issuance of common stock upon noncash exercise of Purchase Rights					$ 2	66			68
Issuance of common stock upon noncash exercise of Purchase Rights, shares					24,350,000
Issuance of common stock upon conversion of notes					$ 1	15			16
Issuance of common stock upon conversion of notes, shares					9,768,291
Stock-based compensation						219			219
Change in fair value of financial instruments attributed to credit risk change (Note 4)							(256)		(256)
Series E-1 Shares dividends	$ 47							(47)	(47)
Series E-1 Shares dividends, shares	47
Net income (loss)								1,351	1,351
Balance at Jun. 30, 2024	$ 1,968		$ 2,719		$ 8	$ 823,709	$ (781)	$ (892,251)	$ (69,315)
Temporary equity, Balance, shares at Jun. 30, 2024	1,968	1,968	22,280	22,280
Common stock, Balance, shares at Jun. 30, 2024					82,828,686				82,828,686

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Cash flows from operating activities:
Net loss		$ 1,351	$ (4,809)	$ (8,558)	$ (2,354)	$ (3,458)	$ (10,912)
Adjustments to reconcile net loss to net cash, cash equivalents and restricted cash used in operating activities:
Loss on issuance of financial instruments		25		27		3,300	111
Change in fair value of financial instruments		(3,325)		73		(4,127)	(1,539)
Gain on debt extinguishment						(1,120)		$ (75,300)
Stock-based compensation						456	685
Depreciation				200		19	418
Noncash interest expense						1,109	1,134
Noncash right-of-use asset amortization						82	1,208
Net gain on lease termination	$ (200)						(459)
Net loss on disposal of property and equipment						11	1,858
Changes in operating assets and liabilities:
Trade accounts receivable						1,121	(4,072)
Inventories						637	1,705
Prepaid and other assets						349	2,435
Accounts payable						(987)	2,167
Accrued expenses and other liabilities						1,000	840
Accrued compensation						671	(625)
Operating lease liabilities						(81)	(1,388)
Net cash and restricted cash used in operating activities						(1,018)	(6,434)
Cash flows from investing activities:
Purchases of property and equipment						(14)	(4)
Net cash and restricted cash used in investing activities						(14)	(4)
Cash flows from financing activities:
Proceeds from issuance of common stock - exercise of warrants							160
Borrowings under term notes							2,138
Proceeds from reinstatement of Merger Agreement – Related Party						1,000
Borrowings under short-term debt						397
Payments under notes carried at fair value						(253)
Net cash and restricted cash provided by financing activities						1,144	2,298
Net change in cash, cash equivalents and restricted cash						112	(4,140)
Cash, cash equivalents and restricted cash, beginning of period			$ 580		$ 4,776	580	4,776	4,776
Cash, cash equivalents and restricted cash, end of period	$ 636	$ 692		$ 636		692	636	$ 580
Supplemental disclosure of noncash investing and financing activities:
Issuance of common stock upon exercise of purchase rights						157	186
Series E-1 shares deemed dividends						94
Issuance of common stock upon conversion of notes						51
Issuance of common stock upon exercise of warrants						15
Purchases of property and equipment included in accounts payable and accrued expenses						$ 78

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ 1,351	$ (4,809)	$ (8,558)	$ (2,354)	$ (3,458)	$ (10,912)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Description of Business Evofem is a San Diego-based biopharmaceutical company focused on commercializing innovative products to address unmet needs in women’s sexual and reproductive health. The Company’s first commercial product, Phexxi ® 16.8 18.2 On December 11, 2023, the Company entered into an Agreement and Plan of Merger, as amended, (the Merger Agreement) with Aditxt, Inc., a Delaware corporation (Aditxt) and Adifem, Inc. (f/k/a Adicure, Inc.), a Delaware corporation and a wholly-owned Subsidiary of Aditxt (Merger Sub), respectively, (collectively, the Parties), pursuant to which, and on the terms and subject to the conditions thereof, the Merger Sub is expected to merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Aditxt (the Merger). Note 10 – Subsequent Events Basis of Presentation and Principles of Consolidation The Company prepared the unaudited interim condensed consolidated financial statements included in this Quarterly Report in accordance with accounting principles generally accepted (GAAP) in the United States for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC) related to quarterly reports on Form 10-Q. The Company’s financial statements are presented on a consolidated basis, which include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements do not include all information and disclosures required by GAAP for annual audited financial statements and should be read in conjunction with the Company’s condensed consolidated financial statements and notes thereto for the year ended December 31, 2023 included in its Annual Report on Form 10-K as filed with the SEC on March 27, 2024 (the 2023 Audited Financial Statements). The unaudited interim condensed consolidated financial statements included in this report have been prepared on the same basis as the Company’s audited consolidated financial statements and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations, cash flows, and statements of convertible and redeemable preferred stock and stockholders’ deficit for the periods presented. The results for the three and six months ended June 30, 2024 are not necessarily indicative of the results expected for the full year. The condensed consolidated balance sheet as of December 31, 2023 was derived from the 2023 Audited Financial Statements. Risks, Uncertainties and Going Concern Any disruptions in the commercialization of Phexxi and/or its supply chain could have a material adverse effect on the Company’s business, results of operations and financial condition. The condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities, in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. The Company’s principal operations are related to the commercialization of Phexxi and, following its acquisition in July 2024, SOLOSEC. Additional activities have included raising capital, identifying alternative manufacturing to lower Phexxi cost of goods sold (COGS), seeking ex-U.S. licensing partners and product in-licensing/acquisition opportunities to add non-dilutive capital to the balance sheet, and establishing and maintaining a corporate infrastructure to support a commercial product. The Company has incurred operating losses and negative cash flows from operating activities since inception. As of June 30, 2024, the Company had a working capital deficit of $ 66.0 892.3 Since October 3, 2022, the Company’s common stock has traded on the OTC Venture Market (the OTCQB) of the OTC Markets Group, Inc., a centralized electronic quotation service for over-the-counter securities, under the symbol “EVFM.” The OTCQB imposes, among other requirements, a minimum $ 0.01 per share bid price requirement (the Bid Price Requirement) for continued inclusion on the OTCQB. The closing bid price for the Company’s common stock must remain at or above $ 0.01 per share to comply with the Bid Price Requirement for continued listing. As of August 8, 2024, the closing price was $ 0.01 . Management’s plans to meet its cash flow needs in the next 12 months include generating recurring product revenue from Phexxi and SOLOSEC, restructuring its current payables, and obtaining additional funding through means such as the issuance of its capital stock, non-dilutive financings, or through collaborations or partnerships with other companies, including license agreements for Phexxi in the U.S. or foreign markets, SOLOSEC in foreign markets, or other potential business combinations. The Company anticipates it will continue to incur net losses for the foreseeable future. According to management estimates, liquidity resources as of June 30, 2024 were not sufficient to maintain the Company’s cash flow needs for the twelve months from the date of issuance of these condensed consolidated financial statements. If the Company is not able to obtain the required funding through a significant increase in revenue, equity or debt financings, license agreements for Phexxi and/or SOLOSEC, or other means, or is unable to obtain funding on terms favorable to the Company, or if there is another event of default affecting the notes payable, there will be a material adverse effect on commercialization operations and the Company’s ability to execute its strategic development plan for future growth. If the Company cannot successfully raise additional funding and implement its strategic development plan, the Company may be forced to make further reductions in spending, including spending in connection with its commercialization activities, extend payment terms with suppliers, liquidate assets where possible at a potentially lower amount than as recorded in the condensed consolidated financial statements, suspend or curtail planned operations, or cease operations entirely. Any of these could materially and adversely affect the Company’s liquidity, financial condition and business prospects, and the Company would not be able to continue as a going concern. The Company has concluded that these circumstances and the uncertainties associated with the Company’s ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company’s ability to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto. Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the assumptions used in estimating the fair value of convertible notes, preferred stock, warrants and purchase rights issued; the assumptions used in the valuation of inventory; the useful lives of property and equipment; the recoverability of long-lived assets; and the valuation of deferred tax assets. These assumptions are more fully described in Note 3 – Revenue Note 4 – Debt Note 6 - Fair Value of Financial Instruments Note 7 - Commitments and Contingencies Note 9 - Stock-based Compensation Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, the Chief Executive Officer of the Company, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets. The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held. The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the U.S. and consist of wholesale distributors, retail pharmacies, and mail-order specialty pharmacies. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of June 30, 2024, based on the evaluation of these factors the Company did not record a reserve for expected credit loss. Products are distributed primarily through three major distributors and mail-order pharmacies, who receive service fees calculated as a percentage of the gross sales, and a fee-per-unit shipped, respectively. These entities are not obligated to purchase any set number of units. They distribute products on demand as orders are received. For the three and six months ended June 30, 2024, the Company’s three largest customers combined made up approximately 75 79 81 84 82 87 Significant Accounting Policies There have been no changes to the significant accounting policies that were described in Note 2 – Summary of Significant Accounting Policies Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of readily available cash in checking accounts and money market funds. Restricted cash consists of cash held in monthly time deposit accounts and letters of credit as described in Note 7- Commitments and Contingencies 0.3 0.8 Additionally, the remaining funds of the $ 25.0 For the six months ended June 30, 2023 and 2024, the Company’s cash, cash equivalents, and restricted cash reported within the condensed consolidated statements of cash flows include restricted cash only. Net Income (Loss) Per Share Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. The net income (loss) available to common stockholders is adjusted for amounts in accumulated deficit related to the deemed dividends triggered for certain financial instruments. Such adjustment was immaterial and zero Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2024 2023 Six months ended June 30, 2024 2023 Options to purchase common stock 3,713 4,268 Warrants to purchase common stock 20,807,539 3,642,343 Purchase rights to purchase common stock 1,546,948,899 28,783,233 Convertible debt 2,528,800,006 158,575,812 Series E-1 and F-1 preferred stock 1,574,554,784 - Total 5,671,114,941 191,005,656 (1) The potentially dilutive securities in the table above include all potentially dilutive securities that are not included in the diluted EPS as per U.S. GAAP, whereas the total common stock reserved for future issuance in Note 8 – Convertible and Redeemable Preferred Stock and Stockholders’ Deficit The following table sets forth the computation of net income attributable to common shareholders, weighted average common shares outstanding for diluted net income per share, and diluted net income per share attributable to common shareholders for the three months ended June 30, 2024 (in thousands, except share and per share amounts). Schedule of Weighed Average Common Shares Outstanding for Diluted Net Loss Per Share Three Months Ended 2024 Numerator: Net income attributable to common stockholders $ 1,304 Adjustments: Change in fair value of purchase rights (3,300 ) Net loss attributable to common stockholders $ (1,996 ) Denominator: Weighted average shares used to compute net income attributable to common stockholder, basic 66,773,313 Add: Pro forma 1,546,948,899 Weighted average shares used to compute net loss attributable to common stockholder, diluted 1,613,722,212 Net income per share attributable to common stockholders, diluted $ (0.00 ) Recently Adopted Accounting Pronouncements open to update No significant new standards were adopted during the six months ended June 30, 2024. Recently Issued Accounting Pronouncements — Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standards setting bodies that are adopted as of the specified effective date. In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative , designed to clarify or improve disclosure and presentation requirements on a variety of topics and align the requirements in the FASB Accounting Standards Codification (ASC) with the SEC regulations. This guidance is effective for the Company no later than June 30, 2027. The Company will adopt ASU No. 2023-06 by complying with the various disclosure requirements but does not expect the requirements to have a material impact on the consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU No. 2023-09, Income Taxes: Improvements to Income Tax Disclosures The Company does not believe the impact of any other recently issued standards and any issued but not yet effective standards will have a material impact on its condensed consolidated financial statements upon adoption.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company recognizes revenue from the sale of Phexxi and will recognize future revenue from SOLOSEC in accordance with ASC 606, Revenue from Contracts with Customers In accordance with ASC 606, the Company recognizes revenue when its performance obligation is satisfied by transferring control of the product to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the U.S. and consist of wholesale distributors, retail pharmacies, and mail-order specialty pharmacies. Payment terms typically range from 31 to 66 days, include prompt pay discounts, and vary by customer. Trade accounts receivable due to the Company from contracts with its customers are stated separately in the condensed consolidated balance sheets, net of various allowances as described in the Trade Accounts Receivable policy in Note 2 – Summary of Significant Accounting Policies The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when the performance obligation is satisfied. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue. Products are sold to customers at the wholesale acquisition cost (WAC) or, in some cases, at a discount to WAC. However, the Company records product revenue net of reserves for applicable variable consideration. These types of variable consideration reduce revenue and include the following: ● Distribution services fees ● Prompt pay and other discounts ● Product returns ● Chargebacks ● Rebates ● Patient support programs, including our co-pay programs An estimate for variable consideration is made with each sale and is recorded in conjunction with the revenue being recognized. To calculate the variable consideration, the Company uses the expected value method and the estimated amounts are recorded as a reduction to accounts receivable or as a current liability based on the nature of the allowance and the terms of the related arrangements. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these provisions are analyzed and adjustments are made if necessary. Any adjustments made to these provisions would also affect net product revenue and earnings. In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance, such as Medicaid, versus private commercial insurance. To determine these estimates, the Company relies on historical sales data showing the amount of various end-user consumer types, inventory reports from the wholesale distributors and mail-order specialty pharmacies, and other relevant data reports. The specific considerations that the Company uses in estimating these amounts related to variable consideration are as follows: Distribution services fees Prompt pay and other discount The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recognized. Chargebacks Rebates Patient support programs Product returns The variable considerations discussed above were recorded in the condensed consolidated balance sheets and consisted of $ 0.1 0.3 3.6 3.2

Debt

Debt	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Debt	Debt Convertible Notes Baker Bros. Notes (temporarily owned by Aditxt from December 11, 2023 through February 26, 2024) On April 23, 2020, the Company entered into a Securities Purchase and Security Agreement (the Baker Bros. Purchase Agreement) with certain affiliates of Baker Bros. Advisors LP, as purchasers (the Baker Purchasers), and Baker Bros. Advisors LP, as designated agent, pursuant to which the Company agreed to issue and sell to the Baker Purchasers (i) convertible senior secured promissory notes (the Baker Notes) in an aggregate principal amount of up to $ 25.0 25.0 2,731 4,575 five-year The Baker Notes have a five-year 10.0 10.0 2.6 5.1 2.4 3.8 The Baker Notes were callable by the Company on 10 100 9,356.25 110 110 4,575 On November 20, 2021, the Company entered into the first amendment to the Baker Bros. Purchase Agreement (the First Baker Amendment), in which each Baker Purchaser had the right to convert all or any portion of the Baker Notes into common stock at a conversion price equal to the lesser of (a) $ 4,575 115 115 50 The First Baker Amendment also extended, effective upon the Company’s achievement of the Financing Threshold, the affirmative covenant to achieve $ 100.0 582,886 93.75 Note 8 – Convertible and Redeemable Preferred Stock and Stockholders’ Deficit 0.0154 On March 21, 2022, the Company entered into the second amendment to the Baker Bros. Purchase Agreement (the Second Baker Amendment), which granted each Baker Purchaser the right to convert all or any portion of the Baker Notes into common stock at a conversion price equal to the lesser of (a) $ 725.81 100 100 20 EVOGUARD 93.75 100.0 On September 15, 2022, the Company entered into the third amendment to the Baker Bros. Purchase Agreement (the Third Baker Amendment), pursuant to which the conversion price was amended to $ 26.25 two-year On December 19, 2022, the Company entered into the First Amendment to the Forbearance Agreement (the Amendment) effective as of December 15, 2022 to amend certain provisions of the Forbearance Agreement dated September 15, 2022. The Amendment revised the Forbearance Agreement to (i) amend the Fifth Recital Clause to clarify that the Purchasers consent to any additional indebtedness pari passu 5.0 On March 7, 2023, Baker Bros. Advisors, LP (the Designated Agent) provided a Notice of Event of Default and Reservation of Rights (the Notice of Default) relating to the Baker Bros. Purchase Agreement. The Notice of Default claimed that the Company failed to maintain the “Required Reserve Amount” as required by the Third Baker Amendment. The Designated Agent, at the direction of the Baker Purchasers, accelerated repayment of the outstanding balance payable. As a result, approximately $ 92.7 100.0 On September 8, 2023, the Company entered into the Fourth Amendment to the Baker Bros. Purchase Agreement (the Fourth Baker Amendment) with the Baker Purchasers. The Fourth Amendment amends certain provisions within the Baker Bros. Purchase Agreement including: (i) the rescission of the Notice of Default delivered to the Company on March 7, 2023 and waiver of the Events of Default named therein; (ii) the waiver of any and all other Events of Default existing as of the Fourth Amendment date; (iii) the removal of the conversion feature into shares of Company common stock, including the removal of any requirement to reserve shares of common stock for conversion of the Baker Notes as well as any registration rights related thereto; (iv) the clarification that for the sole purpose of enabling ex-U.S. license agreements for such assets, any Patents, Trademarks or Copyrights acquired after the Effective Date shall be excluded from the definition of Collateral; and, (v) the removal of the requirement for the Company to achieve $ 100 The outstanding balance of the Baker Notes will continue to accrue interest at 10 The Company paid the required $ 1.0 Schedule of Cash payments Determined based Upon the Quarterly Global Net Revenue Quarterly global net revenue Quarterly cash payment ≤ $5.0 million 3% of such global net revenues >$5.0 million and ≤ 3% on net revenue ≤ $5.0 million; 4% on the net revenue over $5.0 million Greater than $7.0 million 3% on the net revenue ≤ $5.0 million; 4% on the net revenue over $5.0 million and up to $7.0 million; 5% on net revenue over $7.0 million The cash payments were payable beginning in the fourth quarter of 2023 and have been timely paid. Regardless of the percentage paid, the quarterly cash payment amounts, along with the $ 1.0 The Fourth Amendment also granted the Company the ability to repurchase the principal amount and accrued and unpaid interest of the Baker Notes for up to a five-year period for the one-time Repurchase Price designated below: Schedule of Repurchase Price Reduction Date of Notes’ Repurchase Repurchase Price On or prior to September 8, 2024 $ 14,000,000 September 9, 2024-September 8, 2025 $ 16,750,000 September 9, 2025-September 8, 2026 $ 19,500,000 September 9, 2026-September 8, 2027 $ 22,250,000 September 9, 2027-September 8, 2028 $ 25,000,000 The Company evaluated whether any of the Embedded Features required bifurcation as a separate component. The Company elected the fair value option (FVO) under ASC 825, Financial Instruments Due to the execution of the Fourth Baker Amendment, the Company reviewed the Baker Notes in accordance with ASC 470, Debt . 15.6 73.2 12.5 75.3 73.2 Note 6 – Fair Value of Financial Instruments As part of the consideration for the Merger, on December 11, 2023, the Baker Purchasers signed an agreement to assign the Baker Notes to Aditxt (the December Assignment Agreement). Upon this December Assignment Agreement, Aditxt assumed all terms under the Baker Notes, with Aditxt becoming the new senior secured debtholder of the Company, governed by the requirements under the Fourth Baker Amendment. The Baker Notes were re-assigned back to the Baker Purchasers on February 26, 2024 (the February Assignment Agreement). Due to the execution of the February Assignment Agreement, the Company reviewed the Baker Notes in accordance with ASC 470. The Baker Notes, having been effectively terminated, were extinguished on February 26, 2024, resulting in removing the fair value of the old Baker Notes of $ 13.5 Note 6 – Fair Value of Financial Instruments As of June 30, 2024, the Baker Notes are recorded at fair value in the condensed consolidated balance sheet as short-term Notes – carried at fair value with a total fair value of $ 12.3 million, and the total outstanding balance including principal and accrued interest is $ 104.3 million. During the three and six months ended June 30, 2024, the Company paid a total of $ 0.3 On July 23, 2024, the Baker Purchasers assigned the Baker Notes to Future Pak, LLC, as discussed in Note 10 – Subsequent Events Adjuvant Notes On October 14, 2020, the Company entered into a Securities Purchase Agreement (the Adjuvant Purchase Agreement) with Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, the Adjuvant Purchasers), pursuant to which the Company sold unsecured convertible promissory notes (the Adjuvant Notes) in aggregate principal amount of $ 25.0 The Adjuvant Notes have a five-year 7.5 8.8 Interest expense for the Adjuvant Notes consist of the following, and is included in other income (expense), net on the condensed consolidated statements of operations for the three and six months ended June 30, 2024 and 2023 (in thousands): Schedule of Interest Expense 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Coupon interest $ 546 $ 507 $ 1,081 $ 1,004 Amortization of issuance costs - 60 28 128 Total $ 546 $ 567 $ 1,109 $ 1,132 The Adjuvant Notes are convertible, subject to customary 4.99 19.99 0.0001 6,843.75 6,843.75 18,750 100.0 On April 4, 2022, the Company entered into the first amendment to the Adjuvant Purchase Agreement (the Adjuvant Amendment). The Adjuvant Amendment extended the affirmative covenant to achieve $ 100.0 678.49 100 100 30 18,750 100.0 The Adjuvant Notes contain various customary affirmative and negative covenants agreed to by the Company. On September 12, 2022, the Company was in default of the Adjuvant Notes due to the default with the Baker Notes under the cross-default provision. On September 15, 2022, the Company entered into a Forbearance Agreement (the Adjuvant Forbearance Agreement) with the Adjuvant Purchasers, pursuant to which the Adjuvant Purchasers agreed to forbear from exercising any of their rights and remedies during the Forbearance Period as defined in therein, but solely with respect to the specified events of default provided under the Adjuvant Forbearance Agreement. On September 15, 2022, the Company also entered into the second amendment to the Adjuvant Purchase Agreement (the Second Adjuvant Amendment), pursuant to which the conversion price per share was reduced to $ 26.25 10 2.9 109,842 Note 8 – Convertible and Redeemable Preferred Stock and Stockholders’ Deficit 0.0154 1,925,093,273 The Adjuvant Notes are accounted for in accordance with authoritative guidance for convertible debt instruments and are classified as current liabilities in the condensed consolidated balance sheets. The aggregate proceeds of $ 25.0 Derivatives and Hedging Note 6 - Fair Value of Financial Instruments The Company was in default of the Adjuvant Notes as of September 30, 2023, due to the failure to meet the cumulative net sales requirement. However, Adjuvant forbore such default in October 2023 and therefore the Company is no longer in default. As of June 30, 2024, the Adjuvant Notes are recorded in the condensed consolidated balance sheet as short-term convertible notes payable with a total balance of $ 29.6 22.5 7.1 28.5 22.5 6.1 Term Notes December 2022 and February, March, April, July, August, and September 2023 Notes (SSNs) The Company entered into eight Securities Purchase Agreements (SPAs) between December 2022 and September 2023 with certain investors. Each of the agreements was materially similar. The variable details of each SPA, such as the principal amount of each note offering, net proceeds, and maturity date, are outlined in the table below. Pursuant to each SPA, the Company agreed to sell in a registered direct offering (i) unsecured 8.0 0.0001 The SSNs’ interest rates are subject to increase to 12 32.5 The Company evaluated the SSNs in accordance with ASC 480 and determined that the Notes were all liability instruments at issuance. The applicable SSNs were then evaluated in accordance with the requirements of ASC 825 and the Company concluded that they were not precluded from electing the fair value option for the applicable SSNs. The Company also evaluated the Warrants in accordance with ASC 480 and determined that the Warrants issued before the Reverse Stock Split in May 2023 were required to be recorded as liabilities at fair value in the Company’s condensed consolidated balance sheets. The applicable SSNs were marked-to-market at each reporting date with changes in fair value recognized in the condensed consolidated statement of operations, unless the change is concluded to be related to changes in the Company’s credit rating, in which case the change was recognized as a component of accumulated other comprehensive loss in the condensed consolidated balance sheets. As a result of the Reverse Stock Split, the Company had sufficient shares available for issuance to cover the potential exercises; therefore, the Warrants that were previously classified as liabilities were marked-to-market and reclassified to equity in May 2023. For the Warrants issued after the Reverse Stock Split, the Company determined they were required to be recorded in equity. On December 21, 2023, warrants to purchase up to 9,972,074 613 22,280 Summary of SSNs and Warrants at Issuance (December 2022 to September 2023): Schedule of SSNs and Warrants Conversion Price Notes Principal At Issuance Net Proceeds Before Issuance Costs Common Preferred Shares Maturity Date At Issuance At 6/30/2023 At 9/30/2023 At 12/31/2023 At 3/31/2024 At 6/30/2024 December 2022 Notes $ 2,308 $ 1,500 369,230 70 12/21/2025 $ 6.25 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 February 2023 Notes (1) 1,385 900 653,538 - 2/17/2026 $ 2.50 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 March 2023 Notes 600 390 240,000 - 3/17/2026 $ 2.50 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 March 2023 Notes (2) 538 350 258,584 - 3/20/2026 $ 2.50 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 April 2023 Notes 769 500 615,384 - 3/6/2026 $ 1.25 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 July 2023 Notes 1,500 975 1,200,000 - 3/6/2026 $ 1.25 N/A $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 August 2023 Notes 1,000 650 799,999 - 8/4/2026 $ 1.25 N/A $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 September 2023 Notes (3) 2,885 1,875 26,997,041 - 9/26/2026 $ 0.13 N/A $ 0.13 $ 0.0615 $ 0.0158 $ 0.0154 Total Offerings $ 10,985 $ 7,140 31,133,776 (1) Warrants include 99,692 (2) Warrants include 43,200 (3) Warrants include 22,189,349 0.13 4,807,692 0.001 Short-term Debt Insurance Premium Finance Agreement In June 2024, the Company entered into an insurance premium finance agreement with First Insurance Funding (FIF) to finance a portion of its current policy year’s Directors and Officers (D&O) and general insurance policies. The total amount financed was $ 0.4 8.57

Balance Sheet Details

Balance Sheet Details	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Details	Balance Sheet Details Inventories Inventories consist of the following (in thousands) for the period indicated: Schedule of Inventories June 30, 2024 December 31, 2023 Raw materials (1) $ 430 $ 520 Work in process 354 386 Finished goods (1) 276 791 Total $ 1,060 $ 1,697 (1) The raw materials and finished goods balances include a combined estimated reserve on obsolescence and excess inventory which might not be sold prior to expiration of $ 0.3 1.3 Prepaid and Other Current Assets Prepaid and other current assets consist of the following (in thousands): Schedule of Prepaid and Other Current Assets June 30, 2024 December 31, 2023 Insurance $ 488 $ 777 Research & development 13 13 Other 344 405 Total $ 845 $ 1,195 Property and Equipment, Net Property and equipment, net, consists of the following (in thousands): Schedule of Property and Equipment Net Useful Life June 30, 2024 December 31, 2023 Research equipment 5 $ 585 $ 586 Computer equipment and software 3 145 647 Construction in-process - 1,146 1,156 Property and equipment gross 1,876 2,389 Less: accumulated depreciation (689 ) (1,186 ) Total, net $ 1,187 $ 1,203 Depreciation expense for property and equipment was immaterial in both the three and six months ended June 30, 2024. Depreciation expense for property and equipment was $ 0.2 0.4 Accrued Expenses Accrued expenses consist of the following (in thousands): Schedule of Accrued Expenses June 30, 2024 December 31, 2023 Clinical trial related costs $ 2,498 $ 2,498 Accrued royalty 1,522 1,146 Other 732 583 Total $ 4,752 $ 4,227

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair Value of Financial Liabilities The following tables summarize the Company’s convertible debt instruments as of June 30, 2024 and December 31, 2023, respectively (in thousands): Schedule of Fair Value of Financial Liabilities Fair Value As of June 30, 2024 Principal Amount Unamortized Issuance Costs Accrued Interest Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 104,315 $ - $ - $ 104,315 $ 12,280 Level 3 Adjuvant Notes (3) 22,500 - 7,146 29,646 N/A N/A December 2022 Notes (1) 935 - - 935 96 Level 3 February 2023 Notes (1) 942 - - 942 97 Level 3 March 2023 Notes (1) 1,161 - - 1,161 120 Level 3 April 2023 Notes (1) 849 - - 849 88 Level 3 July 2023 Notes (1) 1,271 - - 1,271 131 Level 3 August 2023 Notes (1) 1,075 - - 1,075 111 Level 3 September 2023 Notes (1) 3,064 - - 3,064 316 Level 3 Totals $ 136,112 $ - $ 7,146 $ 143,258 $ 13,239 N/A Fair Value As of December 31, 2023 Principal Amount Unamortized Issuance Costs Accrued Interest Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 99,460 $ - $ - $ 99,460 $ 13,510 Level 3 Adjuvant Notes (3) 22,500 (27 ) 6,064 28,537 N/A N/A December 2022 Notes (1) 940 - - 940 118 Level 3 February 2023 Notes (1) 905 - - 905 118 Level 3 March 2023 Notes (1) 1,204 - - 1,204 157 Level 3 April 2023 Notes (1) 816 - - 816 106 Level 3 July 2023 Notes (1) 1,534 - - 1,534 202 Level 3 August 2023 Notes (1) 1,033 - - 1,033 136 Level 3 September 2023 Notes (1) 2,945 - - 2,945 384 Level 3 Totals $ 131,337 $ (27 ) $ 6,064 $ 137,374 $ 14,731 N/A (1) These liabilities are/were carried at fair value in the condensed consolidated balance sheets. As such, the principal and accrued interest was included in the determination of fair value. The related debt issuance costs were expensed. (2) The Baker Notes principal amount includes $ 19.5 13.7 (3) The Adjuvant Notes are recorded in the condensed consolidated balance sheets at their net carrying amount which includes principal and accrued interest, net of unamortized issuance costs. The following tables summarize the Company’s derivative liabilities as of June 30, 2024 and December 31, 2023 as discussed in Note 8 – Convertible and Redeemable Preferred Stock and Stockholders’ Deficit Schedule of Fair Value of Financial Liabilities Fair Value June 30, 2024 December 31, 2023 Leveling Purchase rights $ 942 $ 1,926 Level 3 Total derivative liabilities $ 942 $ 1,926 Change in Fair Value of Level 3 Financial Liabilities The following table summarizes the changes in Level 3 financial liabilities related to Baker Notes and SSNs measured at fair value on a recurring basis for the three and six months ended June 30, 2024 (in thousands): Schedule of Change in Fair Value of Level 3 Financial Liabilities Baker Notes (Assigned to Aditxt; reassigned back to Baker; Note 4) Total SSNs (Note 4) Total Balance at March 31, 2024 $ 12,260 $ 992 $ 13,252 Extinguishment/Conversion - (16 ) (16 ) Payments (253 ) - (253 ) Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Income (Loss) 273 (17 ) 256 Balance at June 30, 2024 $ 12,280 $ 959 $ 13,239 Baker Notes Total SSNs (Note 4) Total Balance at December 31, 2023 $ 13,510 $ 1,221 $ 14,731 Balance at issuance 12,390 - 12,390 Extinguishment/Conversion (13,510 ) (51 ) (13,561 ) Payments (253 ) - (253 ) Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Income (Loss) 143 (211 ) (68 ) Balance at June 30, 2024 $ 12,280 $ 959 $ 13,239 The following table summarizes the changes in Level 3 financial liabilities related to Baker Notes and SSNs measured at fair value on a recurring basis for the three and six months ended June 30, 2023 (in thousands): Baker Notes Total SSNs (Note 4) Total Balance at March 31, 2023 $ 23,800 $ 7 $ 23,807 Balance at issuance - 1 1 Change in fair value presented in the Condensed Consolidated Statements of Operations - 160 160 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Income (Loss) (8,200 ) (168 ) (8,368 ) Balance at June 30, 2023 $ 15,600 $ - $ 15,600 Baker Notes Total SSNs (Note 4) Total Balance at December 31, 2022 $ 39,260 $ 156 $ 39,416 Balance at issuance - 12 12 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Income (Loss) (23,660 ) (168 ) (23,828 ) Balance at June 30, 2023 $ 15,600 $ - $ 15,600 The following table summarizes the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three and six months ended June 30, 2024 (in thousands): Purchase Rights Derivative Liabilities Total Balance at March 31, 2024 $ 4,310 $ 4,310 Balance at issuance 25 25 Exercises (68 ) (68 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (3,325 ) (3,325 ) Balance at June 30, 2024 $ 942 $ 942 Purchase Rights Derivative Liabilities Total Balance at December 31, 2023 $ 1,926 $ 1,926 Balance at issuance 3,300 3,300 Exercises (157 ) (157 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (4,127 ) (4,127 ) Balance at June 30, 2024 $ 942 $ 942 The following table summarizes the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three and six months ended June 30, 2023 (in thousands): May 2022 Public Offering Common Warrants June 2022 Baker Warrants December 2022 Warrants February and March 2023 Warrants Purchase Rights Derivative Liabilities Total Balance at March 31, 2023 $ 6 $ 3 $ 1 $ 6 $ 106 $ 122 Balance at issuance - - - - 26 26 Exercises (1 ) - - - (6 ) (7 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (4 ) (2 ) (1 ) (4 ) (73 ) (84 ) Reclassified to equity (1 ) (1 ) - (2 ) (53 ) (57 ) Balance at June 30, 2023 $ - $ - $ - $ - $ - $ - April and June 2020 Baker Warrants May 2022 Public Offering Common Warrants June 2022 Baker Warrants December 2022 Warrants February and March 2023 Warrants Purchase Rights Derivative Liabilities Total Balance at December 31, 2022 $ 1 $ 303 $ 170 $ 107 $ - $ 1,095 $ 1,676 Balance at issuance - - - - 6 105 111 Exercises - (7 ) - - - (186 ) (193 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (1 ) (295 ) (169 ) (107 ) (6 ) (961 ) (1,539 ) Reclassified to equity - (1 ) (1 ) - - (53 ) (55 ) Balance at June 30, 2023 $ - $ - $ - $ - $ - $ - $ - Valuation Methodology From the third quarter of 2022 through the second quarter of 2023, the fair value of the Baker Notes issued, as described in Note 4 – Debt Starting in the third quarter of 2023, the fair value of the Baker Notes, issued as described in Note 4 – Debt 5.0 15.0 The fair value of the Baker Notes is subject to uncertainty due to the assumptions that are used in the Monte Carlo simulation-based model. These factors include but are not limited to the Company’s future revenue, and the probability and timing of the exercise of the repurchase right. The fair value of the Baker Notes is sensitive to these estimated inputs made by management that are used in the calculation. SSNs The fair values of the SSNs issued, as described in Note 4 – Debt 0.2 million change in fair value of financial instruments attributed to credit risk change in the condensed consolidated comprehensive statement of operations. The quarterly valuation adjustments for the three months ended June 30, 2023 were recorded as a $ 0.2 million change in fair value of financial instruments in the condensed consolidated statement of operations and a $ 0.2 million change in fair value of financial instruments attributed to credit risk change in the condensed consolidated comprehensive statement of operations. The quarterly valuation adjustments for the six months ended June 30, 2023 were recorded as a $ 0.2 million change in fair value of financial instruments attributed to credit risk change in the condensed consolidated comprehensive statement of operations. Purchase Rights The Adjuvant Purchase Rights and the May Note Purchase Rights (collectively Purchase Rights) are recorded as derivative liabilities in the condensed consolidated balance sheets. The Purchase Rights are valued using an OPM, like a Black-Scholes Methodology with changes in the fair value being recorded in the condensed consolidated statements of operations. The assumptions used in the OPM are considered level 3 assumptions and include, but are not limited to, the market value of invested capital, the cumulative equity value of the Company as a proxy for the exercise price and the expected term the Purchase Rights will be held prior to exercise and a risk-free interest rate. Warrants Warrants previously classified as liabilities were reclassified as equity instruments during the second quarter of 2023 as a result of the Reverse Stock Split. The Company will continue to re-evaluate the classification of its warrants at the close of each reporting period to determine their proper balance sheet classification. The warrants are valued using an OPM based on the applicable assumptions, which include the exercise price of the warrants, time to expiration, expected volatility of our peer group, risk-free interest rate, and expected dividends. The assumptions used in the OPM are considered level 3 assumptions and include, but are not limited to, the market value of invested capital, the cumulative equity value of the Company as a proxy for the exercise price, the expected term the warrants will be held prior to exercise, a risk-free interest rate, and probability of change of control event. Additionally, because the warrants are re-priced under certain provisions in the agreements, at each re-pricing event the Company must value the warrants using a Black-Scholes model immediately prior to and immediately following the re-pricing event. The incremental fair value is recorded as an increase to accumulated deficit and additional paid-in-capital, in accordance with ASC 470.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases Fleet Lease In December 2019, the Company and Enterprise FM Trust (the Lessor) entered into a Master Equity Lease Agreement whereby the Company leases vehicles to be delivered by the Lessor from time to time with various monthly costs depending on whether the vehicles are delivered for a term of 24 36 19 0.3 Leases In September 2022, the Company extended the lease term for an additional 12 24 12 24 2020 Lease and the First Amendment On October 3, 2019, the Company entered into an office lease for approximately 24,474 0.8 On April 14, 2020, the Company entered into the first amendment to the 2020 Lease for an additional 8,816 0.05 On March 20, 2023, the Company received a notice of default from its landlord for failing to timely pay March 2023 rent, resulting in a breach under the agreement. As a result, the Company’s letter of credit in the amount of $ 0.8 3.3 4.2 0.2 2022 Sublease On May 27, 2022, the Company entered into a sublease agreement with AMN Healthcare, Inc. (AMN), pursuant to which the Company agreed to sublease 16,637 0.1 3.5 0.3 Supplemental Financial Statement Information Schedule of Lease Cost Three Months Ended June 30, Six Months Ended June 30, Lease Cost (in thousands) Classification 2024 2023 2024 2023 Operating lease expense Research and development $ 1 $ 59 $ 2 $ 125 Operating lease expense Selling and marketing 43 88 95 247 Operating lease expense General and administrative 2 103 5 334 Total $ 46 $ 250 $ 102 $ 706 Schedule of Lease Term and Discount Rate Lease Term and Discount Rate June 30, 2024 December 31, 2023 Weighted Average Remaining Lease Term (in years) 0.92 0.75 Weighted Average Discount Rate 12 % 12 % Schedule of Operating Lease Maturities Maturity of Operating Lease Liabilities (in thousands) June 30, 2024 Remainder of 2024 (6 months) $ 66 Year ending December 31, 2025 55 Total lease payments 121 Less imputed interest (7 ) Total $ 114 Schedule of Supplement Cash Outflows in Operating Leases Other information (in thousands) 2024 2023 Six Months Ended June 30, Other information (in thousands) 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows in operating leases $ 140 $ 1,427 Other Contractual Commitments In November 2019, the Company entered into a supply and manufacturing agreement with a third-party to manufacture Phexxi, with potential to manufacture other product candidates, in accordance with all applicable current good manufacturing practice regulations. There was approximately $ 0.3 no Contingencies From time to time the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. During the year ended December 31, 2023, the Company settled a portion of its trade payables with numerous vendors, which resulted in a $ 2.1 92 On December 14, 2020, a trademark dispute captioned TherapeuticsMD, Inc. v Evofem Biosciences, Inc., was filed in the U.S. District Court for the Southern District of Florida against the Company, alleging trademark infringement of certain trademarks owned by TherapeuticsMD under federal and state law (Case No. 9:20-cv-82296). On July 18, 2022, the Company settled the lawsuit with TherapeuticsMD, with certain requirements which are required to be performed by July 2024, including changing the name of Phexxi. The Company is currently working on how to resolve this issue. Intellectual Property Rights In 2014, the Company entered into an amended and restated license agreement (the Rush License Agreement) with Rush University Medical Center (Rush University) pursuant to which Rush University granted the Company an exclusive, worldwide license of certain patents and know-how related to its multipurpose vaginal pH modulator technology. For the U.S. patent that the Company licensed from Rush University, multiple Orders Granting Interim Extension (OGIEs) have been received from the United States Patent and Trademark Office (USPTO), currently extending the expiration of this patent to March 2025. Pursuant to the Rush License Agreement, the Company is obligated to pay Rush University an earned royalty based upon a percentage of net sales in the range of mid-single digits until the expiration of this patent. In September 2020, the Company entered into the first amendment to the Rush License Agreement, pursuant to which the Company is also obligated to pay a minimum annual royalty amount of $ 0.1 0.1 0.2 0.4 0.2 0.3 1.5 1.1

Convertible and Redeemable Pref

Convertible and Redeemable Preferred Stock and Stockholders’ Deficit	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Convertible and Redeemable Preferred Stock and Stockholders’ Deficit	Convertible and Redeemable Preferred Stock and Stockholders’ Deficit Warrants In April and June 2020, pursuant to the Baker Bros. Purchase Agreement, as discussed in Note 4 – Debt 2,732 4,575 0.0154 In May 2022, the Company completed an underwritten public offering (the May 2022 Public Offering) which included the issuance of common warrants to purchase 362,640 93.75 205,360 93.63 five-year 894,194 0.0154 In June 2022, as required by the Second Baker Amendment, the Company issued the June 2022 Baker Warrants to purchase up to 582,886 0.0001 93.75 five-year 4.99 19.99 0.0154 In February, March, April, July, August, and September 2023, pursuant to the SSNs as discussed in Note 4 – Debt 1,152,122 2,615,383 1.25 0.13 0.0154 On December 21, 2023, warrants to purchase up to 9,972,074 613 As of June 30, 2024, warrants to purchase up to 20,807,539 2.42 , Schedule of Warrants Type of Warrants Underlying common stock to be Purchased Exercise Price Issue Date Exercise Period Common Warrants 451 $ 14,062.50 May 24, 2018 May 24, 2018 to May 24 2025 Common Warrants 888 $ 11,962.50 April 11, 2019 October 11, 2019 to April 11, 2026 Common Warrants 1,480 $ 11,962.50 June 10, 2019 December 10, 2019 to June 10, 2026 Common Warrants 1,639 $ 0.0154 April 24, 2020 April 24, 2020 to April 24, 2025 Common Warrants 1,092 $ 0.0154 June 9, 2020 June 9, 2020 to June 9, 2025 Common Warrants 8,003 $ 735.00 January 13, 2022 March 1, 2022 to March 1, 2027 Common Warrants 8,303 $ 897.56 March 1, 2022 March 1, 2022 to March 1, 2027 Common Warrants 6,666 $ 309.56 May 4, 2022 May 4, 2022 to May 4, 2027 Common Warrants 894,194 $ 0.0154 May 24, 2022 May 24, 2022 to May 24, 2027 Common Warrants 582,886 $ 0.0154 June 28, 2022 May 24, 2022 to June 28, 2027 Common Warrants 49,227 $ 0.0154 December 21, 2022 December 21, 2022 to December 21, 2027 Common Warrants 130,461 $ 0.0154 February 17, 2023 February 17, 2023 to February 17, 2028 Common Warrants 258,584 $ 0.0154 March 20, 2023 March 20, 2023 to March 20, 2028 Common Warrants 369,231 $ 0.0154 April 5, 2023 April 5, 2023 to April 5, 2028 Common Warrants 349,463 $ 0.0154 July 3, 2023 July 3, 2023 to July 3, 2028 Common Warrants 615,384 $ 0.0154 August 4, 2023 August 4, 2023 to August 4, 2028 Common Warrants 12,721,893 $ 0.0154 September 27, 2023 September 27, 2023 to September 27, 2028 Prefunded Common Warrants 4,807,694 $ 0.0010 September 27, 2023 September 27, 2023 to September 27, 2028 Total 20,807,539 Preferred Stock Effective December 15, 2021, the Company amended and restated its certificate of incorporation, under which the Company is currently authorized to issue up to 5,000,000 0.0001 Convertible and Redeemable Preferred Stock On August 7, 2023, the Company filed a Certificate of Designation of Series E-1 Convertible Preferred Stock (E-1 Certificate of Designation), par value $ 0.0001 2,300 0.40 25 On August 7, 2023, certain investors party to the December 2022 Notes and the February 2023 Notes exchanged $ 1.8 1,800 0.0154 1.8 0.1 On December 11, 2023, the Company filed a Certificate of Designation of Series F-1 Convertible Preferred Stock (F-1 Certificate of Designation), par value $ 0.0001 95,000 0.0635 0.0154 On December 21, 2023, the Company issued a total of 22,280 613 9,972,074 21,667 Nonconvertible and Redeemable Preferred Stock On December 16, 2022, the Company filed a Certificate of Designation of Series D Non-Convertible Preferred Stock (the D Certificate of Designation), par value $ 0.0001 70 1 70 Note 4 – Debt Common Stock Effective September 14, 2023, the Company further amended its amended and restated certificate of incorporation to increase the number of authorized shares of common stock to 3,000,000,000 Purchase Rights On September 15, 2022, the Company entered into certain exchange agreements with the Adjuvant Purchasers and the May 2022 Notes Purchasers to exchange, upon request, the Purchase Rights for an aggregate of 942,080 Note 6 – Fair Value of Financial Instruments In 2023, the Company signed an additional agreement with the holders of the Purchase Rights which fixed the total aggregate value of the Purchase Rights at $ 24.7 21,667 In connection with the SSNs issuances, during the three and six months ended June 30, 2024, the number of outstanding Purchase Rights increased by 16,303,657 1,161,636,815 15,218,227 24,966,856 During the three months ended June 30, 2024, the Company issued 24,350,000 1,546,948,899 Common Stock Reserved for Future Issuance Common stock reserved for future issuance is as follows in common equivalent shares as of June 30, 2024: Summary of Common Stock Reserved for Future Issuance Common stock issuable upon the exercise of stock options outstanding 3,713 Common stock issuable upon the exercise of common stock warrants 10,598,201 Common stock available for future issuance under the 2019 ESPP 509 Common stock available for future issuance under the Amended and Restated 2014 Plan 5,823 Common stock available for future issuance under the Amended Inducement Plan 609 Common stock reserved for the exercise of purchase rights 741,490,642 Common stock reserved for the conversion of convertible notes 155,468,037 Common stock reserved for the conversion of series E-1 preferred stock 37,770,024 Total common stock reserved for future issuance 945,337,558 (1) The potentially dilutive securities in Note 2 – Summary of Significant Accounting Policies

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation Equity Incentive Plans The following table summarizes stock-based compensation expense related to stock options granted to employees, non-employee directors and consultants included in the condensed consolidated statements of operations as follows (in thousands): Schedule of Stock-based Compensation Expense Related to Stock Options 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Research and development $ 10 $ 29 $ 26 $ 69 Selling and marketing 24 47 59 104 General and administrative 185 192 371 512 Total $ 219 $ 268 $ 456 $ 685 Stock Options There were no 0.6 1.2 Employee Stock Purchase Plan The purchase price under the 2019 ESPP is 85 25,000 Restricted Stock Awards There were no shares of performance-based RSAs granted to the Company’s executive management team in any period presented. For performance-based RSAs, (i) the fair value of the award is determined on the grant date; (ii) the Company assesses the probability of achieving each individual milestone associated with the award using reasonable assumptions based on the Company’s operation performance towards each milestone; (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met; and (iv) the Company reassesses the probability of achieving each individual milestone at each reporting date, and any change in estimate is accounted for through a cumulative adjustment in the period when the change in estimate occurs. Non-performance based RSAs are valued at the fair value on the grant date and the associated expenses will be recognized over the vesting period. As of June 30, 2024, there was no

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Baker Notes Assignment On July 23, 2024, the Company consented to the transfer of ownership of the Company’s senior secured notes from Baker Brothers Life Sciences, L.P., a Delaware limited partnership, 667, L.P., a Delaware limited partnership and Baker Bros. Advisors, LP, a Delaware limited partnership to the successor Future Pak, LLC, a Michigan limited liability company (the Assignee). The terms of the senior secured notes were not changed in connection with the assignment from Baker to the Assignee. Issuance of Series F-1 Preferred Shares to Aditxt The Company issued a total of 1,000 shares of its Series F-1 Preferred Shares to Aditxt for an aggregate purchase price of $ 1.0 million in July and August 2024, as per the A&R Merger Agreement. The powers, preferences, rights, qualifications, limitations and restrictions applicable to the F-1 Preferred Stock are set forth in the F-1 Preferred Stock certificate of designation, as filed with the US Securities and Exchange Commission (the Commission) in that Current Report on Form 8-K dated on December 12, 2023. In connection with the closing of the above, the Company entered into a Registration Rights Agreement (the Registration Rights Agreement) with Aditxt, which provides that the Company will register the resale the shares of Company common stock issuable upon conversion of the F-1 Preferred Shares. The Company is required to prepare and file a registration statement on Form S-3 with the Commission no later than the 300th calendar day following the signing date for the Purchase Agreement and to use its commercially reasonable efforts to have the registration statement declared effective by the Commission within 90 days of the filing of such registration statement, subject to certain exceptions and specified penalties if timely effectiveness is not achieved. The Company has also agreed to, among other things, indemnify Aditxt, its officers, directors, agents, partners, members, managers, stockholders, affiliates, investment advisers and employees of each of them under the registration statement from certain liabilities and pay all fees and expenses (excluding any underwriting discounts and selling commissions) incident to the Company’s obligations under the Registration Rights Agreement. License and Supply Agreement On July 17, 2024, Evofem entered into a License and Supply Agreement with Pharma 1 Drug Store, LLC, for the exclusive commercialization rights for Phexxi in certain countries in the Middle East (the Territory), including the United Arab Emirates (UAE), Kuwait, Saudi Arabia, and Qatar. Pharma 1 is responsible for obtaining and maintaining any regulatory approvals required to market and sell Phexxi and will handle all aspects of distribution, sales and marketing, pharmacovigilance and all other commercial functions related to Phexxi in the Territory, assuming regulatory approvals. Under the License Agreement, Pharma 1 shall create a Development Plan (as defined in the License Agreement) to pursue all reasonable actions necessary to obtain governmental approval of (i) Phexxi and (ii) any related formulation of the Company’s licensed technology whether now existing or subsequently developed (the Product) in the Territory. Furthermore, subject to the terms and conditions of the License Agreement, the Company granted to Pharma 1 an exclusive, royalty-free, sublicensable license to the Product to advertise, promote, distribute for commercial sale, offer for sale, sell, and import for commercial sale the Licensed Product in the Territory. Within three months from the Effective Date, Pharma 1 must file the regulatory dossier for the Product with the UAE. Within twelve months of the Effective Date, Pharma 1 must place an order for sufficient quantities of the Product to support commercial launch of the Product in the UAE. Within eighteen months after the last governmental approval of the Product, Pharma 1 must seek governmental approval of the Product in a different country/state in the Territory. As consideration for the License Agreement, Pharma 1 has agreed to pay the Company the cost to manufacture the Product, plus a fee, and has agreed to maintain an inventory of the Product reasonably sufficient to satisfy at least four months’ worth of its requirements at all times for the duration of the Term. The License Agreement contains customary representations, warranties and indemnities of the Company and Pharma 1 relating to the Product Asset Purchase Agreement On July 14, 2024, Evofem entered into an Asset Purchase Agreement (the SOLOSEC Agreement), with Lupin, Inc. (Lupin) to expand its women’s health product portfolio with the acquisition of all of the global rights and title to Lupin’s SOLOSEC ® Amended and Restated Plan of Merger On July 12, 2024, the Company, Aditxt, and the Merger Sub entered into an Amended and Restated Merger Agreement (the A&R Merger Agreement). The A&R Merger Agreement amends and restates in its entirely the Agreement and Plan of Merger (as amended January 10, 2024, January 30, 2024, February 29, 2024, and May 2, 2024 (collectively, the Original Merger Agreement). Except as described below, the terms and provisions of the A&R Merger Agreement are consistent with the terms and provision of the Original Merger Agreement. As consideration for the Merger, the Parent will (i) pay to Common Stockholders an amount equal to $ 1.8 Additionally, each share of the Company’s Series E-1 Shares issued and outstanding as of the Effective Time (as defined in the A&R Merger Agreement) shall automatically be converted into the right to receive from Aditxt one share of Parent Preferred Stock (the Preferred Merger Consideration, and together with the Common Consideration the Merger Consideration). At the Effective Time of the Merger: (i) the Company Convertible Note Holders will enter into an Exchange Agreement, pursuant to which these Note Holders will exchange the value of their then-outstanding Company Convertible Notes and purchase rights for an aggregate of not more than 88,161 (ii) each stock option of the Company (Options) that was outstanding and unexercised immediately prior to the Effective Time will be cancelled without the right to receive any consideration. (iii) all shares of Company Common Stock or Company Preferred Stock held by Parent or Merger Sub or by any wholly-owned Subsidiary thereof shall be automatically cancelled and retired and shall cease to exist, and no consideration shall be delivered or deliverable in exchange therefor; Further, Aditxt agreed to, on or prior to: (a) July 12, 2024, purchase 500 shares of the Company’s Series F-1 Preferred Shares for an aggregate purchase price of $ 0.5 million (the July Purchase) (b) August 9, 2024, purchase an additional 500 shares of F-1 Preferred Shares for an aggregate purchase price of $ 0.5 million (the August Purchase), (c) the earlier of August 30, 2024 or within five business days of the closing of a public offering by Aditxt resulting in aggregate net proceeds to Aditxt of no less than $ 20.0 million, purchase an additional 2,000 shares of F-1 Preferred Shares for an aggregate purchase price of $ 2.0 million; and (d) September 30, 2024, purchase an additional 1,000 shares of F-1 Preferred Stock at an aggregate purchase price of $ 1.0 million. The July Purchase and subsequent August Purchase of 500 shares of the Company’s Series F-1 Preferred Shares in each respective purchase were completed as scheduled. The A&R Merger Agreement is subject to certain closing conditions and contains customary representations, warranties and covenants and indemnifications provisions. The consummation of the Merger is conditioned upon, among other things: (i) the Company Shareholder approval shall having been obtained in accordance with applicable Law; (ii) no governmental entity having jurisdiction over any party shall have issue any order, decree, ruling injunction or other action that is in effect restraining the Merger; (iii) a voting agreement shall have been executed and delivered by the parties thereto; (iv) all Company preferred stock shall have been converted to Company common stock except for the Unconverted Company Preferred Stock (as defined by the A&R Merger Agreement); (v) the Company shall have received agreements from all of the holders of the Company’s warrants, duly executed, containing waivers with respect to any fundamental transaction, change in control or other similar rights that such warrant holders may have under any such Company warrants and exchange such Company warrants as they hold for an aggregate of not more than 930,336 0.15 4,141,434 98 The Company will prepare and file a proxy statement with the U.S. SEC and, subject to certain exceptions, the Company’s Board of Directors will recommend that the A&R Merger Agreement be adopted by the Company’s stockholders at a special meeting of the Company’s stockholders (the Company Board Recommendation). However, subject to the satisfaction of certain terms and conditions, the Company and the Board, as applicable, are permitted to take certain actions which may, as more fully described in the A&R Merger Agreement, include changing the Company Board Recommendation and entering into a definitive agreement with respect to a Company Change of Recommendation (as defined in the A&R Merger Agreement) if the Company Board or any committee thereof determines in good faith, after consultation with the Company’s outside legal and financial advisors and after taking into account relevant legal, financial, regulatory, estimated timing of consummation and other aspects of such proposal that the Company Board considers in good faith and the Person or group making such proposal, would, if consummated in accordance with its terms, result in a transaction more favorable to the Company Shareholders than the Merger. If the Company has a Company Change of Recommendation, the Company must provide Aditxt with a ten (10) calendar day written notice thereof and negotiate with Aditxt in good faith to provide a competing offer. The Board has (i) determined that the A&R Merger Agreement and the transactions contemplated thereby, including the Merger, are advisable and in the best interests of the Company and its stockholders, and declared it advisable for the Company to enter into the A&R Merger Agreement, (ii) approved and declared advisable the execution and delivery by the Company of the A&R Merger Agreement, the performance by the Company of its covenants and agreements contained in the A&R Merger Agreement and the consummation of the Merger and the other transactions contemplated by the A&R Merger Agreement upon the terms and subject to the conditions contained therein, (iii) directed that the adoption of the A&R Merger Agreement be submitted to a vote at a meeting of the Company stockholders and (iv) resolved, subject to the terms and conditions set forth in the Merger Agreement, to recommend that the Company stockholders adopt the Merger Agreement. Warrants and Purchase Rights Exercises and Notes Conversions Subsequent to June 30, 2024, 17,500,000 Purchase Rights were exercised in cashless transactions for an equivalent number of shares of common stock.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto. Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the assumptions used in estimating the fair value of convertible notes, preferred stock, warrants and purchase rights issued; the assumptions used in the valuation of inventory; the useful lives of property and equipment; the recoverability of long-lived assets; and the valuation of deferred tax assets. These assumptions are more fully described in Note 3 – Revenue Note 4 – Debt Note 6 - Fair Value of Financial Instruments Note 7 - Commitments and Contingencies Note 9 - Stock-based Compensation
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, the Chief Executive Officer of the Company, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets. The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held. The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the U.S. and consist of wholesale distributors, retail pharmacies, and mail-order specialty pharmacies. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of June 30, 2024, based on the evaluation of these factors the Company did not record a reserve for expected credit loss. Products are distributed primarily through three major distributors and mail-order pharmacies, who receive service fees calculated as a percentage of the gross sales, and a fee-per-unit shipped, respectively. These entities are not obligated to purchase any set number of units. They distribute products on demand as orders are received. For the three and six months ended June 30, 2024, the Company’s three largest customers combined made up approximately 75 79 81 84 82 87
Significant Accounting Policies	Significant Accounting Policies There have been no changes to the significant accounting policies that were described in Note 2 – Summary of Significant Accounting Policies
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of readily available cash in checking accounts and money market funds. Restricted cash consists of cash held in monthly time deposit accounts and letters of credit as described in Note 7- Commitments and Contingencies 0.3 0.8 Additionally, the remaining funds of the $ 25.0 For the six months ended June 30, 2023 and 2024, the Company’s cash, cash equivalents, and restricted cash reported within the condensed consolidated statements of cash flows include restricted cash only.
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. The net income (loss) available to common stockholders is adjusted for amounts in accumulated deficit related to the deemed dividends triggered for certain financial instruments. Such adjustment was immaterial and zero Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2024 2023 Six months ended June 30, 2024 2023 Options to purchase common stock 3,713 4,268 Warrants to purchase common stock 20,807,539 3,642,343 Purchase rights to purchase common stock 1,546,948,899 28,783,233 Convertible debt 2,528,800,006 158,575,812 Series E-1 and F-1 preferred stock 1,574,554,784 - Total 5,671,114,941 191,005,656 (1) The potentially dilutive securities in the table above include all potentially dilutive securities that are not included in the diluted EPS as per U.S. GAAP, whereas the total common stock reserved for future issuance in Note 8 – Convertible and Redeemable Preferred Stock and Stockholders’ Deficit The following table sets forth the computation of net income attributable to common shareholders, weighted average common shares outstanding for diluted net income per share, and diluted net income per share attributable to common shareholders for the three months ended June 30, 2024 (in thousands, except share and per share amounts). Schedule of Weighed Average Common Shares Outstanding for Diluted Net Loss Per Share Three Months Ended 2024 Numerator: Net income attributable to common stockholders $ 1,304 Adjustments: Change in fair value of purchase rights (3,300 ) Net loss attributable to common stockholders $ (1,996 ) Denominator: Weighted average shares used to compute net income attributable to common stockholder, basic 66,773,313 Add: Pro forma 1,546,948,899 Weighted average shares used to compute net loss attributable to common stockholder, diluted 1,613,722,212 Net income per share attributable to common stockholders, diluted $ (0.00 )
Recently Adopted Accounting Pronouncements open to update	Recently Adopted Accounting Pronouncements open to update No significant new standards were adopted during the six months ended June 30, 2024.
Recently Issued Accounting Pronouncements — Not Yet Adopted	Recently Issued Accounting Pronouncements — Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standards setting bodies that are adopted as of the specified effective date. In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative , designed to clarify or improve disclosure and presentation requirements on a variety of topics and align the requirements in the FASB Accounting Standards Codification (ASC) with the SEC regulations. This guidance is effective for the Company no later than June 30, 2027. The Company will adopt ASU No. 2023-06 by complying with the various disclosure requirements but does not expect the requirements to have a material impact on the consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU No. 2023-09, Income Taxes: Improvements to Income Tax Disclosures The Company does not believe the impact of any other recently issued standards and any issued but not yet effective standards will have a material impact on its condensed consolidated financial statements upon adoption.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2024 2023 Six months ended June 30, 2024 2023 Options to purchase common stock 3,713 4,268 Warrants to purchase common stock 20,807,539 3,642,343 Purchase rights to purchase common stock 1,546,948,899 28,783,233 Convertible debt 2,528,800,006 158,575,812 Series E-1 and F-1 preferred stock 1,574,554,784 - Total 5,671,114,941 191,005,656
Schedule of Weighed Average Common Shares Outstanding for Diluted Net Loss Per Share	The following table sets forth the computation of net income attributable to common shareholders, weighted average common shares outstanding for diluted net income per share, and diluted net income per share attributable to common shareholders for the three months ended June 30, 2024 (in thousands, except share and per share amounts). Schedule of Weighed Average Common Shares Outstanding for Diluted Net Loss Per Share Three Months Ended 2024 Numerator: Net income attributable to common stockholders $ 1,304 Adjustments: Change in fair value of purchase rights (3,300 ) Net loss attributable to common stockholders $ (1,996 ) Denominator: Weighted average shares used to compute net income attributable to common stockholder, basic 66,773,313 Add: Pro forma 1,546,948,899 Weighted average shares used to compute net loss attributable to common stockholder, diluted 1,613,722,212 Net income per share attributable to common stockholders, diluted $ (0.00 )

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of Cash payments Determined based Upon the Quarterly Global Net Revenue	Schedule of Cash payments Determined based Upon the Quarterly Global Net Revenue Quarterly global net revenue Quarterly cash payment ≤ $5.0 million 3% of such global net revenues >$5.0 million and ≤ 3% on net revenue ≤ $5.0 million; 4% on the net revenue over $5.0 million Greater than $7.0 million 3% on the net revenue ≤ $5.0 million; 4% on the net revenue over $5.0 million and up to $7.0 million; 5% on net revenue over $7.0 million
Schedule of Repurchase Price Reduction	The Fourth Amendment also granted the Company the ability to repurchase the principal amount and accrued and unpaid interest of the Baker Notes for up to a five-year period for the one-time Repurchase Price designated below: Schedule of Repurchase Price Reduction Date of Notes’ Repurchase Repurchase Price On or prior to September 8, 2024 $ 14,000,000 September 9, 2024-September 8, 2025 $ 16,750,000 September 9, 2025-September 8, 2026 $ 19,500,000 September 9, 2026-September 8, 2027 $ 22,250,000 September 9, 2027-September 8, 2028 $ 25,000,000
Schedule of Interest Expense	Interest expense for the Adjuvant Notes consist of the following, and is included in other income (expense), net on the condensed consolidated statements of operations for the three and six months ended June 30, 2024 and 2023 (in thousands): Schedule of Interest Expense 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Coupon interest $ 546 $ 507 $ 1,081 $ 1,004 Amortization of issuance costs - 60 28 128 Total $ 546 $ 567 $ 1,109 $ 1,132
Schedule of SSNs and Warrants	Summary of SSNs and Warrants at Issuance (December 2022 to September 2023): Schedule of SSNs and Warrants Conversion Price Notes Principal At Issuance Net Proceeds Before Issuance Costs Common Preferred Shares Maturity Date At Issuance At 6/30/2023 At 9/30/2023 At 12/31/2023 At 3/31/2024 At 6/30/2024 December 2022 Notes $ 2,308 $ 1,500 369,230 70 12/21/2025 $ 6.25 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 February 2023 Notes (1) 1,385 900 653,538 - 2/17/2026 $ 2.50 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 March 2023 Notes 600 390 240,000 - 3/17/2026 $ 2.50 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 March 2023 Notes (2) 538 350 258,584 - 3/20/2026 $ 2.50 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 April 2023 Notes 769 500 615,384 - 3/6/2026 $ 1.25 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 July 2023 Notes 1,500 975 1,200,000 - 3/6/2026 $ 1.25 N/A $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 August 2023 Notes 1,000 650 799,999 - 8/4/2026 $ 1.25 N/A $ 0.0845 $ 0.0615 $ 0.0158 $ 0.0154 September 2023 Notes (3) 2,885 1,875 26,997,041 - 9/26/2026 $ 0.13 N/A $ 0.13 $ 0.0615 $ 0.0158 $ 0.0154 Total Offerings $ 10,985 $ 7,140 31,133,776 (1) Warrants include 99,692 (2) Warrants include 43,200 (3) Warrants include 22,189,349 0.13 4,807,692 0.001

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands) for the period indicated: Schedule of Inventories June 30, 2024 December 31, 2023 Raw materials (1) $ 430 $ 520 Work in process 354 386 Finished goods (1) 276 791 Total $ 1,060 $ 1,697 (1) The raw materials and finished goods balances include a combined estimated reserve on obsolescence and excess inventory which might not be sold prior to expiration of $ 0.3 1.3
Schedule of Prepaid and Other Current Assets	Prepaid and other current assets consist of the following (in thousands): Schedule of Prepaid and Other Current Assets June 30, 2024 December 31, 2023 Insurance $ 488 $ 777 Research & development 13 13 Other 344 405 Total $ 845 $ 1,195
Schedule of Property and Equipment Net	Property and equipment, net, consists of the following (in thousands): Schedule of Property and Equipment Net Useful Life June 30, 2024 December 31, 2023 Research equipment 5 $ 585 $ 586 Computer equipment and software 3 145 647 Construction in-process - 1,146 1,156 Property and equipment gross 1,876 2,389 Less: accumulated depreciation (689 ) (1,186 ) Total, net $ 1,187 $ 1,203
Schedule of Accrued Expenses	Accrued expenses consist of the following (in thousands): Schedule of Accrued Expenses June 30, 2024 December 31, 2023 Clinical trial related costs $ 2,498 $ 2,498 Accrued royalty 1,522 1,146 Other 732 583 Total $ 4,752 $ 4,227

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2024
Short-Term Debt [Line Items]
Schedule of Fair Value of Financial Liabilities	The following tables summarize the Company’s derivative liabilities as of June 30, 2024 and December 31, 2023 as discussed in Note 8 – Convertible and Redeemable Preferred Stock and Stockholders’ Deficit Schedule of Fair Value of Financial Liabilities Fair Value June 30, 2024 December 31, 2023 Leveling Purchase rights $ 942 $ 1,926 Level 3 Total derivative liabilities $ 942 $ 1,926
Schedule of Change in Fair Value of Level 3 Financial Liabilities	The following table summarizes the changes in Level 3 financial liabilities related to Baker Notes and SSNs measured at fair value on a recurring basis for the three and six months ended June 30, 2024 (in thousands): Schedule of Change in Fair Value of Level 3 Financial Liabilities Baker Notes (Assigned to Aditxt; reassigned back to Baker; Note 4) Total SSNs (Note 4) Total Balance at March 31, 2024 $ 12,260 $ 992 $ 13,252 Extinguishment/Conversion - (16 ) (16 ) Payments (253 ) - (253 ) Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Income (Loss) 273 (17 ) 256 Balance at June 30, 2024 $ 12,280 $ 959 $ 13,239 Baker Notes Total SSNs (Note 4) Total Balance at December 31, 2023 $ 13,510 $ 1,221 $ 14,731 Balance at issuance 12,390 - 12,390 Extinguishment/Conversion (13,510 ) (51 ) (13,561 ) Payments (253 ) - (253 ) Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Income (Loss) 143 (211 ) (68 ) Balance at June 30, 2024 $ 12,280 $ 959 $ 13,239 The following table summarizes the changes in Level 3 financial liabilities related to Baker Notes and SSNs measured at fair value on a recurring basis for the three and six months ended June 30, 2023 (in thousands): Baker Notes Total SSNs (Note 4) Total Balance at March 31, 2023 $ 23,800 $ 7 $ 23,807 Balance at issuance - 1 1 Change in fair value presented in the Condensed Consolidated Statements of Operations - 160 160 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Income (Loss) (8,200 ) (168 ) (8,368 ) Balance at June 30, 2023 $ 15,600 $ - $ 15,600 Baker Notes Total SSNs (Note 4) Total Balance at December 31, 2022 $ 39,260 $ 156 $ 39,416 Balance at issuance - 12 12 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Income (Loss) (23,660 ) (168 ) (23,828 ) Balance at June 30, 2023 $ 15,600 $ - $ 15,600 The following table summarizes the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three and six months ended June 30, 2024 (in thousands): Purchase Rights Derivative Liabilities Total Balance at March 31, 2024 $ 4,310 $ 4,310 Balance at issuance 25 25 Exercises (68 ) (68 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (3,325 ) (3,325 ) Balance at June 30, 2024 $ 942 $ 942 Purchase Rights Derivative Liabilities Total Balance at December 31, 2023 $ 1,926 $ 1,926 Balance at issuance 3,300 3,300 Exercises (157 ) (157 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (4,127 ) (4,127 ) Balance at June 30, 2024 $ 942 $ 942 The following table summarizes the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three and six months ended June 30, 2023 (in thousands): May 2022 Public Offering Common Warrants June 2022 Baker Warrants December 2022 Warrants February and March 2023 Warrants Purchase Rights Derivative Liabilities Total Balance at March 31, 2023 $ 6 $ 3 $ 1 $ 6 $ 106 $ 122 Balance at issuance - - - - 26 26 Exercises (1 ) - - - (6 ) (7 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (4 ) (2 ) (1 ) (4 ) (73 ) (84 ) Reclassified to equity (1 ) (1 ) - (2 ) (53 ) (57 ) Balance at June 30, 2023 $ - $ - $ - $ - $ - $ - April and June 2020 Baker Warrants May 2022 Public Offering Common Warrants June 2022 Baker Warrants December 2022 Warrants February and March 2023 Warrants Purchase Rights Derivative Liabilities Total Balance at December 31, 2022 $ 1 $ 303 $ 170 $ 107 $ - $ 1,095 $ 1,676 Balance at issuance - - - - 6 105 111 Exercises - (7 ) - - - (186 ) (193 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (1 ) (295 ) (169 ) (107 ) (6 ) (961 ) (1,539 ) Reclassified to equity - (1 ) (1 ) - - (53 ) (55 ) Balance at June 30, 2023 $ - $ - $ - $ - $ - $ - $ -
Convertible Debt [Member]
Short-Term Debt [Line Items]
Schedule of Fair Value of Financial Liabilities	The following tables summarize the Company’s convertible debt instruments as of June 30, 2024 and December 31, 2023, respectively (in thousands): Schedule of Fair Value of Financial Liabilities Fair Value As of June 30, 2024 Principal Amount Unamortized Issuance Costs Accrued Interest Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 104,315 $ - $ - $ 104,315 $ 12,280 Level 3 Adjuvant Notes (3) 22,500 - 7,146 29,646 N/A N/A December 2022 Notes (1) 935 - - 935 96 Level 3 February 2023 Notes (1) 942 - - 942 97 Level 3 March 2023 Notes (1) 1,161 - - 1,161 120 Level 3 April 2023 Notes (1) 849 - - 849 88 Level 3 July 2023 Notes (1) 1,271 - - 1,271 131 Level 3 August 2023 Notes (1) 1,075 - - 1,075 111 Level 3 September 2023 Notes (1) 3,064 - - 3,064 316 Level 3 Totals $ 136,112 $ - $ 7,146 $ 143,258 $ 13,239 N/A Fair Value As of December 31, 2023 Principal Amount Unamortized Issuance Costs Accrued Interest Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 99,460 $ - $ - $ 99,460 $ 13,510 Level 3 Adjuvant Notes (3) 22,500 (27 ) 6,064 28,537 N/A N/A December 2022 Notes (1) 940 - - 940 118 Level 3 February 2023 Notes (1) 905 - - 905 118 Level 3 March 2023 Notes (1) 1,204 - - 1,204 157 Level 3 April 2023 Notes (1) 816 - - 816 106 Level 3 July 2023 Notes (1) 1,534 - - 1,534 202 Level 3 August 2023 Notes (1) 1,033 - - 1,033 136 Level 3 September 2023 Notes (1) 2,945 - - 2,945 384 Level 3 Totals $ 131,337 $ (27 ) $ 6,064 $ 137,374 $ 14,731 N/A (1) These liabilities are/were carried at fair value in the condensed consolidated balance sheets. As such, the principal and accrued interest was included in the determination of fair value. The related debt issuance costs were expensed. (2) The Baker Notes principal amount includes $ 19.5 13.7 (3) The Adjuvant Notes are recorded in the condensed consolidated balance sheets at their net carrying amount which includes principal and accrued interest, net of unamortized issuance costs.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lease Cost	Schedule of Lease Cost Three Months Ended June 30, Six Months Ended June 30, Lease Cost (in thousands) Classification 2024 2023 2024 2023 Operating lease expense Research and development $ 1 $ 59 $ 2 $ 125 Operating lease expense Selling and marketing 43 88 95 247 Operating lease expense General and administrative 2 103 5 334 Total $ 46 $ 250 $ 102 $ 706
Schedule of Lease Term and Discount Rate	Schedule of Lease Term and Discount Rate Lease Term and Discount Rate June 30, 2024 December 31, 2023 Weighted Average Remaining Lease Term (in years) 0.92 0.75 Weighted Average Discount Rate 12 % 12 %
Schedule of Operating Lease Maturities	Schedule of Operating Lease Maturities Maturity of Operating Lease Liabilities (in thousands) June 30, 2024 Remainder of 2024 (6 months) $ 66 Year ending December 31, 2025 55 Total lease payments 121 Less imputed interest (7 ) Total $ 114
Schedule of Supplement Cash Outflows in Operating Leases	Schedule of Supplement Cash Outflows in Operating Leases Other information (in thousands) 2024 2023 Six Months Ended June 30, Other information (in thousands) 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows in operating leases $ 140 $ 1,427

Convertible and Redeemable Pr_2

Convertible and Redeemable Preferred Stock and Stockholders’ Deficit (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Warrants	Schedule of Warrants Type of Warrants Underlying common stock to be Purchased Exercise Price Issue Date Exercise Period Common Warrants 451 $ 14,062.50 May 24, 2018 May 24, 2018 to May 24 2025 Common Warrants 888 $ 11,962.50 April 11, 2019 October 11, 2019 to April 11, 2026 Common Warrants 1,480 $ 11,962.50 June 10, 2019 December 10, 2019 to June 10, 2026 Common Warrants 1,639 $ 0.0154 April 24, 2020 April 24, 2020 to April 24, 2025 Common Warrants 1,092 $ 0.0154 June 9, 2020 June 9, 2020 to June 9, 2025 Common Warrants 8,003 $ 735.00 January 13, 2022 March 1, 2022 to March 1, 2027 Common Warrants 8,303 $ 897.56 March 1, 2022 March 1, 2022 to March 1, 2027 Common Warrants 6,666 $ 309.56 May 4, 2022 May 4, 2022 to May 4, 2027 Common Warrants 894,194 $ 0.0154 May 24, 2022 May 24, 2022 to May 24, 2027 Common Warrants 582,886 $ 0.0154 June 28, 2022 May 24, 2022 to June 28, 2027 Common Warrants 49,227 $ 0.0154 December 21, 2022 December 21, 2022 to December 21, 2027 Common Warrants 130,461 $ 0.0154 February 17, 2023 February 17, 2023 to February 17, 2028 Common Warrants 258,584 $ 0.0154 March 20, 2023 March 20, 2023 to March 20, 2028 Common Warrants 369,231 $ 0.0154 April 5, 2023 April 5, 2023 to April 5, 2028 Common Warrants 349,463 $ 0.0154 July 3, 2023 July 3, 2023 to July 3, 2028 Common Warrants 615,384 $ 0.0154 August 4, 2023 August 4, 2023 to August 4, 2028 Common Warrants 12,721,893 $ 0.0154 September 27, 2023 September 27, 2023 to September 27, 2028 Prefunded Common Warrants 4,807,694 $ 0.0010 September 27, 2023 September 27, 2023 to September 27, 2028 Total 20,807,539
Summary of Common Stock Reserved for Future Issuance	Common stock reserved for future issuance is as follows in common equivalent shares as of June 30, 2024: Summary of Common Stock Reserved for Future Issuance Common stock issuable upon the exercise of stock options outstanding 3,713 Common stock issuable upon the exercise of common stock warrants 10,598,201 Common stock available for future issuance under the 2019 ESPP 509 Common stock available for future issuance under the Amended and Restated 2014 Plan 5,823 Common stock available for future issuance under the Amended Inducement Plan 609 Common stock reserved for the exercise of purchase rights 741,490,642 Common stock reserved for the conversion of convertible notes 155,468,037 Common stock reserved for the conversion of series E-1 preferred stock 37,770,024 Total common stock reserved for future issuance 945,337,558 (1) The potentially dilutive securities in Note 2 – Summary of Significant Accounting Policies

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense Related to Stock Options	The following table summarizes stock-based compensation expense related to stock options granted to employees, non-employee directors and consultants included in the condensed consolidated statements of operations as follows (in thousands): Schedule of Stock-based Compensation Expense Related to Stock Options 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Research and development $ 10 $ 29 $ 26 $ 69 Selling and marketing 24 47 59 104 General and administrative 185 192 371 512 Total $ 219 $ 268 $ 456 $ 685

Description of Business and B_2

Description of Business and Basis of Presentation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Aug. 08, 2024	Oct. 03, 2022
Product Information [Line Items]
Revenue from product sales	$ 4,160	$ 2,458	$ 7,763	$ 8,267
Working capital deficit	66,000		66,000
Accumulated deficit	$ 892,251		$ 892,251		$ 888,699
Share Price								$ 0.01
Subsequent Event [Member]
Product Information [Line Items]
Share Price							$ 0.01
Phexxi [Member]
Product Information [Line Items]
Revenue from product sales					$ 18,200	$ 16,800

Schedule of Potentially Dilutiv

Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,671,114,941	191,005,656
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,713	4,268
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	20,807,539	3,642,343
Rights [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,546,948,899	28,783,233
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,528,800,006	158,575,812
Series E One and F One Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,574,554,784

Schedule of Weighed Average Com

Schedule of Weighed Average Common Shares Outstanding for Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income attributable to common stockholders	$ 1,304	$ (8,558)	$ (3,552)	$ (10,912)
Change in fair value of purchase rights	(3,300)
Net loss attributable to common stockholders	$ (1,996)
Weighted average shares used to compute net income attributable to common stockholder, basic	66,773,313	1,576,158	48,983,853	1,654,026
Weighted average shares used to compute net loss attributable to common stockholder, diluted	1,613,722,212	1,576,158	48,983,853	1,654,026
Net income per share attributable to common stockholders, diluted	$ 0	$ (5.43)	$ (0.07)	$ (6.60)
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Pro forma adjustments to reflect assumed exercise of outstanding purchase rights	1,546,948,899

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Product Information [Line Items]
Proceeds from issuancde of notes			$ 25
Down round feature, decrease in net income (loss) to common shareholder, amount	$ 0	$ 0	0	$ 0
Building and Building Improvements [Member]
Product Information [Line Items]
Letters of credit		$ 0.3		$ 0.3
Building and Building Improvements [Member] | Letter of Credit [Member]
Product Information [Line Items]
Letter of credit, breach of contract			$ 0.8
Revenue Benchmark [Member] | Three Largest Customers Combined [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage	75%	81%	79%	84%
Accounts Receivable [Member] | Four Largest Customers Combined [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage			82%		87%

Revenue (Details Narrative)

Revenue (Details Narrative) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Trade accounts receivable	$ 0.1	$ 0.3
Other liabilities, current	$ 3.6	$ 3.2

Schedule of Cash payments Deter

Schedule of Cash payments Determined based Upon the Quarterly Global Net Revenue (Details)	1 Months Ended
	Sep. 30, 2023
Quarterly Global Net Revenue One [Member]
Short-Term Debt [Line Items]
Quarterly cash payment	3% of such global net revenues
Quarterly Global Net Revenue Two [Member]
Short-Term Debt [Line Items]
Quarterly cash payment	3% on net revenue ≤ $5.0 million;
Quarterly Global Net Revenue Three [Member]
Short-Term Debt [Line Items]
Quarterly cash payment	3% on the net revenue ≤ $5.0 million;

Schedule of Repurchase Price Re

Schedule of Repurchase Price Reduction (Details) - Baker Notes [Member]	Sep. 08, 2023 USD ($)
Prior To September 8, 2024 [Member]
Debt Instrument [Line Items]
Debt instrument, repurchase amount	$ 14,000,000
September 9, 2024 - September 8, 2025 [Member]
Debt Instrument [Line Items]
Debt instrument, repurchase amount	16,750,000
September 9, 2025 - September 8, 2026 [Member]
Debt Instrument [Line Items]
Debt instrument, repurchase amount	19,500,000
September 9, 2026 - September 8, 2027 [Member]
Debt Instrument [Line Items]
Debt instrument, repurchase amount	22,250,000
September 9, 2027 - September 8, 2028 [Member]
Debt Instrument [Line Items]
Debt instrument, repurchase amount	$ 25,000,000

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Debt Disclosure [Abstract]
Coupon interest	$ 546	$ 507	$ 1,081	$ 1,004
Amortization of issuance costs		60	28	128
Total	$ 546	$ 567	$ 1,109	$ 1,132

Schedule of SSNs and Warrants (

Schedule of SSNs and Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
		Jun. 30, 2024		Mar. 31, 2024		Dec. 31, 2023		Sep. 30, 2023	Jun. 30, 2023		Dec. 31, 2022
Short-Term Debt [Line Items]
Preferred Shares		0				0
December 2022 Notes [Member]
Short-Term Debt [Line Items]
Principal At Issuance		$ 2,308
Net Proceeds Before Issuance Costs		$ 1,500
Common Warrants		369,230
Preferred Shares		70
Maturity Date		Dec. 21, 2025
Conversion price		$ 0.0154		$ 0.0158		$ 0.0615		$ 0.0845	$ 0.8125		$ 6.25
February 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal At Issuance	[1]	$ 1,385
Net Proceeds Before Issuance Costs	[1]	$ 900
Common Warrants	[1]	653,538
Maturity Date	[1]	Feb. 17, 2026
Conversion price	[1]	$ 0.0154		0.0158		0.0615		0.0845	0.8125		2.50
March 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal At Issuance		$ 600
Net Proceeds Before Issuance Costs		$ 390
Common Warrants		240,000
Maturity Date		Mar. 17, 2026
Conversion price		$ 0.0154		0.0158		0.0615		0.0845	0.8125		2.50
March Two 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal At Issuance	[2]	$ 538
Net Proceeds Before Issuance Costs	[2]	$ 350
Common Warrants	[2]	258,584
Maturity Date	[2]	Mar. 20, 2026
Conversion price		$ 0.0154	[2]	0.0158	[2]	0.0615	[2]	0.0845	0.8125	[2]	2.50	[2]
April 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal At Issuance		$ 769
Net Proceeds Before Issuance Costs		$ 500
Common Warrants		615,384
Maturity Date		Mar. 06, 2026
Conversion price		$ 0.0154	[2]	0.0158	[2]	0.0615		0.0845	$ 0.8125		1.25
July 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal At Issuance		$ 1,500
Net Proceeds Before Issuance Costs		$ 975
Common Warrants		1,200,000
Maturity Date		Mar. 06, 2026
Conversion price		$ 0.0154	[2]	0.0158	[2]	0.0615		0.0845			1.25
August 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal At Issuance		$ 1,000
Net Proceeds Before Issuance Costs		$ 650
Common Warrants		799,999
Maturity Date		Aug. 04, 2026
Conversion price		$ 0.0154	[2]	0.0158	[2]	0.0615		0.0845			1.25
September 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal At Issuance	[3]	$ 2,885
Net Proceeds Before Issuance Costs	[3]	$ 1,875
Common Warrants	[3]	26,997,041
Maturity Date	[3]	Sep. 26, 2026
Conversion price	[3]	$ 0.0154		$ 0.0158		$ 0.0615		$ 0.13			$ 0.13
Senior Subordinated Notes [Member]
Short-Term Debt [Line Items]
Principal At Issuance		$ 10,985
Net Proceeds Before Issuance Costs		$ 7,140
Common Warrants		31,133,776
[1]Warrants include 99,692 43,200 22,189,349 0.13 4,807,692 0.001

Schedule of SSNs and Warrants_2

Schedule of SSNs and Warrants (Details) (Parenthetical) - $ / shares	Jun. 30, 2024	Sep. 30, 2023	Mar. 31, 2023	Feb. 28, 2023	May 31, 2022
Short-Term Debt [Line Items]
Warrants					894,194
Warrants exercise price	$ 2.42
Placement Agent [Member] | December Two Thousand Twenty Two To September Two Thousand Twenty Three [Member]
Short-Term Debt [Line Items]
Number of shares to purchase capital stock			43,200	99,692
Placement Agent [Member] | December Two Thousand Twenty Two To September Two Thousand Twenty Three [Member] | Series A Preferred Stock [Member]
Short-Term Debt [Line Items]
Warrants		22,189,349
Warrants exercise price		$ 0.13
Placement Agent [Member] | December Two Thousand Twenty Two To September Two Thousand Twenty Three [Member] | Series B Preferred Stock [Member]
Short-Term Debt [Line Items]
Warrants		4,807,692
Warrants exercise price		$ 0.001

Debt (Details Narrative)

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands												3 Months Ended		6 Months Ended		12 Months Ended
	Oct. 01, 2023	Sep. 08, 2023	Mar. 07, 2023	Dec. 19, 2022	Sep. 15, 2022	Apr. 04, 2022	Mar. 21, 2022	Nov. 20, 2021	Oct. 14, 2020	Jun. 09, 2020	Apr. 24, 2020	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Feb. 26, 2024	Dec. 21, 2023	Aug. 07, 2023	Dec. 31, 2022	Sep. 30, 2022	May 31, 2022	Apr. 23, 2020
Debt Instrument [Line Items]
Warrant exercise price per share												$ 2.42		$ 2.42
Interest expense														$ 1,109	$ 1,134
Proceeds from issuance of sale of equity								$ 50,000
Debt covenant, cumulative net sales requirement													$ 100,000		100,000
Exercise price												$ 0.0154		$ 0.0154
Debt instrument periodic payment			$ 92,700
Cumulative net sales		$ 100,000
Accrued interest percentage		10%
Interest revenue expenses net	$ 1,000
Gain on extinguishment of debt														$ 1,120		$ 75,300
Revalued amount extinguishment of debt amount																$ 73,200
Common stock, par value (in usd per share)												$ 0.0001		$ 0.0001		$ 0.0001				$ 0.0001
Redemption premium percentage																			25%
Warrants to purchase up																						894,194
Finance Agreement [Member]
Debt Instrument [Line Items]
Principal amount												$ 400		$ 400
Interest rate												8.57%		8.57%
Series F-1 Shares [Member]
Debt Instrument [Line Items]
Warrants outstanding												22,280		22,280				22,280
Common Stock [Member]
Debt Instrument [Line Items]
Warrants to purchase up																		9,972,074
Warrants outstanding																		613
June 2022 Baker Warrants [Member]
Debt Instrument [Line Items]
Warrants purchase								582,886
Warrant exercise price per share								$ 93.75
Baker Warrants [Member]
Debt Instrument [Line Items]
Warrant exercise price per share												$ 0.0154		$ 0.0154
Baker Bros. Notes [Member]
Debt Instrument [Line Items]
Warrants term										5 years
Debt instrument, term					2 years
Debt instrument conversion price per share								$ 4,575
Conversion price as a percentage of lowest stock price								115%
Conversion price threshold percentage							100%
Convertible notes payable fair value		$ 12,500										$ 13,239		$ 13,239		$ 14,731	$ 13,500
Accrued interest												104,300		104,300
Cash payments												300		300
Baker Bros. Notes [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Principal amount																							$ 25,000
Debt instrument, term											5 years
Debt instrument conversion rate											10%
Debt instrument interest rate effective percent											10%
Interest expense												2,600	2,400	5,100	3,800
Written notice period											10 days
Debt instrument, benchmark price per share											$ 9,356.25
Debt instrument conversion price per share											$ 4,575
Baker Bros. Notes [Member] | Convertible Notes Payable [Member] | Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage											100%
Baker Bros. Notes [Member] | Convertible Notes Payable [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage											110%
Baker Bros. Notes [Member] | Baker Second Closing Notes [Member]
Debt Instrument [Line Items]
Principal amount										$ 25,000
Warrants purchase										2,731
Warrant exercise price per share										$ 4,575
Second Baker Amendment [Member]
Debt Instrument [Line Items]
Debt instrument conversion price per share							$ 725.81
Debt covenant, cumulative net sales requirement													100,000		100,000
Conversion price threshold percentage							100%
Proceeds from issuance of common stock							$ 20,000
Second Baker Amendment [Member] | Baker Warrants [Member]
Debt Instrument [Line Items]
Warrant exercise price per share																					$ 93.75
Third Baker Amendment [Member]
Debt Instrument [Line Items]
Debt instrument conversion price per share					$ 26.25
Secured Creditor Forbearance Agreement [Member]
Debt Instrument [Line Items]
Debt instrument indebtedness amount				$ 5,000
Old Baker Notes [Member]
Debt Instrument [Line Items]
Notes payable fair value																15,600
Accumulated other comprehensive income																73,200
Short-term Convertible Notes [Member]
Debt Instrument [Line Items]
Convertible notes payable fair value												$ 12,300		$ 12,300
Adjuvant Notes [Member]
Debt Instrument [Line Items]
Debt instrument interest rate effective percent												8.80%		8.80%
Debt instrument conversion price per share						$ 678.49						$ 0.0154		$ 0.0154
Conversion price as a percentage of lowest stock price						100%
Convertible notes payable fair value												$ 29,646		$ 29,646		28,537
conversion share														1,925,093,273
Adjuvant Notes [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Principal amount									$ 25,000
Debt instrument, term									5 years
Debt instrument conversion rate														7.50%
Debt instrument conversion price per share					$ 26.25				$ 6,843.75
Debt covenant, cumulative net sales requirement													$ 100,000		$ 100,000
Beneficial ownership limitation percentage									4.99%
Beneficial ownership limitation percentage									19.99%
Common stock, par value (in usd per share)									$ 0.0001
Debt instrument weighted average price per share						$ 18,750			$ 18,750
Debt instrument weighted average period						30 days
Debt instrument convertible exchange percentage					10%
Debt Conversion, Converted Instrument, Amount					$ 2,900
Debt conversion converted instrument amount					109,842
Restricted Cash					$ 25,000
Convertible debt												29,600		$ 29,600		28,500
Convertible debt, current principal amount												22,500		22,500		22,500
Convertible debt, current, accrued interest												$ 7,100		$ 7,100		$ 6,100
8.0% Senior Subordinated Notes Due 2025 Issued December 2022 [Member]
Debt Instrument [Line Items]
Redemption premium percentage																				32.50%
8.0% Senior Subordinated Notes Due 2025 Issued December 2022 [Member] | Unsecured Debt [Member]
Debt Instrument [Line Items]
Interest rate																				8%
Interest rate increase																				12%

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($) $ in Thousands		Jun. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	[1]	$ 430	$ 520
Work in process		354	386
Finished goods	[1]	276	791
Total		$ 1,060	$ 1,697
[1]The raw materials and finished goods balances include a combined estimated reserve on obsolescence and excess inventory which might not be sold prior to expiration of $ 0.3 1.3

Schedule of Inventories (Deta_2

Schedule of Inventories (Details) (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventory adjustments	$ 0.3	$ 0.3
Inventory write-down	$ 1.3

Schedule of Prepaid and Other C

Schedule of Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Insurance	$ 488	$ 777
Research & development	13	13
Other	344	405
Total	$ 845	$ 1,195

Schedule of Property and Equipm

Schedule of Property and Equipment Net (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 1,876	$ 2,389
Less: accumulated depreciation	(689)	(1,186)
Total, net	1,187	1,203
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 585	586
Useful Life	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 145	647
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 1,146	$ 1,156

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Clinical trial related costs	$ 2,498	$ 2,498
Accrued royalty	1,522	1,146
Other	732	583
Total	$ 4,752	$ 4,227

Balance Sheet Details (Details

Balance Sheet Details (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation expense	$ 200	$ 19	$ 418

Schedule of Fair Value of Finan

Schedule of Fair Value of Financial Liabilities (Details) - USD ($) $ in Thousands		Jun. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities		$ 942	$ 1,926
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities		942	1,926
Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		136,112	131,337
Unamortized Issuance Costs			(27)
Accrued Interest		7,146	6,064
Net Carrying Amount		143,258	137,374
Fair Value Amount		13,239	14,731
Unamortized Issuance Costs			27
Baker Bros. Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[1],[2]	104,315	99,460
Unamortized Issuance Costs	[1],[2]
Accrued Interest	[1],[2]
Net Carrying Amount	[1],[2]	104,315	99,460
Fair Value Amount	[1],[2]	12,280	13,510
Unamortized Issuance Costs	[1],[2]
Adjuvant Notes [Member] | Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unamortized Issuance Costs	[3]		(27)
Accrued Interest	[3]	7,146	6,064
Unamortized Issuance Costs	[3]		27
Adjuvant Notes [Member] | Convertible Debt [Member] | Reported Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net Carrying Amount	[3]	29,646	28,537
Adjuvant Notes [Member] | Convertible Debt [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Amount	[3]
Adjuvant Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[3]	22,500
Fair Value Amount	[3]		22,500
December 2022 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		2,308
December 2022 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	935	940
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net Carrying Amount	[2]	935	940
Fair Value Amount	[2]	96	118
Unamortized Issuance Costs	[2]
February 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[4]	1,385
February 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	942	905
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net Carrying Amount	[2]	942	905
Fair Value Amount	[2]	97	118
Unamortized Issuance Costs	[2]
March 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		600
March 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	1,161	1,204
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net Carrying Amount	[2]	1,161	1,204
Fair Value Amount	[2]	120	157
Unamortized Issuance Costs	[2]
April 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		769
April 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	849	816
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net Carrying Amount	[2]	849	816
Fair Value Amount	[2]	88	106
Unamortized Issuance Costs	[2]
July 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		1,500
July 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	1,271	1,534
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net Carrying Amount	[2]	1,271	1,534
Fair Value Amount	[2]	131	202
Unamortized Issuance Costs	[2]
August 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		1,000
August 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	1,075	1,033
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net Carrying Amount	[2]	1,075	1,033
Fair Value Amount	[2]	111	136
Unamortized Issuance Costs	[2]
September 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[5]	2,885
September 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	3,064	2,945
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net Carrying Amount	[2]	3,064	2,945
Fair Value Amount	[2]	316	384
Unamortized Issuance Costs	[2]
[1]The Baker Notes principal amount includes $ 19.5 13.7 99,692 22,189,349 0.13 4,807,692 0.001

Schedule of Fair Value of Fin_2

Schedule of Fair Value of Financial Liabilities (Details) (Parenthetical) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Baker Notes [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Interest paid in kind	$ 19.5	$ 13.7

Schedule of Change in Fair Valu

Schedule of Change in Fair Value of Level 3 Financial Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Reclassified to equity		$ 53
Long-Term Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 13,252	23,807	$ 14,731	$ 39,416
Extinguishment/conversion	(16)	1	(13,561)	12
Payments	(253)		(253)
Change in fair value presented in the Condensed Consolidated Statements of Operations	256	(8,368)	(68)	(23,828)
Ending balance	13,239	15,600	13,239	15,600
Balance at issuance			12,390
Extinguishment/conversion			(12,390)
Change in fair value presented in the Condensed Consolidated Statements of Operations		160
Long-Term Debt [Member] | Baker Notes Assigned To Aditxt Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	12,260	23,800	13,510	39,260
Extinguishment/conversion			(13,510)
Payments	(253)		(253)
Change in fair value presented in the Condensed Consolidated Statements of Operations	273	(8,200)	143	(23,660)
Ending balance	12,280	15,600	12,280	15,600
Balance at issuance			12,390
Extinguishment/conversion			(12,390)
Change in fair value presented in the Condensed Consolidated Statements of Operations
Long-Term Debt [Member] | Total Offerings [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	992	7	1,221	156
Extinguishment/conversion	(16)	1	(51)	12
Payments
Change in fair value presented in the Condensed Consolidated Statements of Operations	(17)	(168)	(211)	(168)
Ending balance	959		959
Balance at issuance
Extinguishment/conversion
Change in fair value presented in the Condensed Consolidated Statements of Operations		160
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	4,310	122	1,926	1,676
Change in fair value presented in the Condensed Consolidated Statements of Operations	(3,325)	(84)	(4,127)	(1,539)
Ending balance	942		942
Balance at issuance	25	26	3,300	111
Extinguishment/conversion	(25)	(26)	(3,300)	(111)
Exercises	(68)	(7)	(157)	(193)
Reclassified to equity		(57)		(55)
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | Rights [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	4,310	106	1,926	1,095
Change in fair value presented in the Condensed Consolidated Statements of Operations	(3,325)	(73)	(4,127)	(961)
Ending balance	942		942
Balance at issuance	25	26	3,300	105
Extinguishment/conversion	(25)	(26)	(3,300)	(105)
Exercises	$ (68)	(6)	$ (157)	(186)
Reclassified to equity		(53)		(53)
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | May 2022 Public Offering Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		6		303
Change in fair value presented in the Condensed Consolidated Statements of Operations		(4)		(295)
Ending balance
Balance at issuance
Extinguishment/conversion
Exercises		(1)		(7)
Reclassified to equity		(1)		(1)
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | June 2022 Baker Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		3		170
Change in fair value presented in the Condensed Consolidated Statements of Operations		(2)		(169)
Ending balance
Balance at issuance
Extinguishment/conversion
Exercises
Reclassified to equity		(1)		(1)
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | December 2022 Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		1		107
Change in fair value presented in the Condensed Consolidated Statements of Operations		(1)		(107)
Ending balance
Balance at issuance
Extinguishment/conversion
Exercises
Reclassified to equity
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | February and March 2023 Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		6
Change in fair value presented in the Condensed Consolidated Statements of Operations		(4)		(6)
Ending balance
Balance at issuance				6
Extinguishment/conversion				(6)
Exercises
Reclassified to equity		(2)
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Liability Convertible Preferred Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance				1
Change in fair value presented in the Condensed Consolidated Statements of Operations				(1)
Ending balance
Balance at issuance
Extinguishment/conversion
Exercises
Reclassified to equity

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details Narrative) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Baker Bros. Notes [Member] | Measurement Input Royalty Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input	0.050		0.050
Baker Bros. Notes [Member] | Measurement Input, Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input	0.150		0.150
Senior Subordinated Notes [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Change in fair value of financial instruments	$ 0.2	$ 0.2	$ 0.2	$ 0.2

Schedule of Lease Cost (Details

Schedule of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Loss Contingencies [Line Items]
Operating lease expense	$ 46	$ 250	$ 102	$ 706
Research and Development Expense [Member]
Loss Contingencies [Line Items]
Operating lease expense	1	59	2	125
Selling and Marketing Expense [Member]
Loss Contingencies [Line Items]
Operating lease expense	43	88	95	247
General and Administrative Expense [Member]
Loss Contingencies [Line Items]
Operating lease expense	$ 2	$ 103	$ 5	$ 334

Schedule of Lease Term and Disc

Schedule of Lease Term and Discount Rate (Details)	Jun. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Weighted Average Remaining Lease Term (in years)	11 months 1 day	9 months
Weighted Average Discount Rate	12%	12%

Schedule of Operating Lease Mat

Schedule of Operating Lease Maturities (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2024 (6 months)	$ 66
Year ending December 31, 2025	55
Total lease payments	121
Less imputed interest	(7)
Total	$ 114

Schedule of Supplement Cash Out

Schedule of Supplement Cash Outflows in Operating Leases (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Operating cash outflows in operating leases	$ 140	$ 1,427

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) $ in Thousands			1 Months Ended		2 Months Ended	3 Months Ended		6 Months Ended
	May 27, 2022 USD ($) ft²	Jan. 01, 2021 USD ($)	Jun. 30, 2023 USD ($)	Sep. 30, 2022	Jun. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) Integer	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Mar. 20, 2023 USD ($)	Apr. 14, 2020 USD ($) ft²	Dec. 31, 2019	Oct. 03, 2019 USD ($) ft²
Loss Contingencies [Line Items]
Number of leased vehicles | Integer								19
Restricted cash					$ 692	$ 692		$ 692		$ 580
Square footage | ft²												8,816		24,474
Operating lease right-of-use assets					114	114		114		106	$ 3,300
Operating lease liabilities					$ 1	1		1		8	4,200
Gain on termination of lease			$ 200						$ 459
Company area (in square feet) | ft²	16,637
Lease expenses	$ 100
Lease percentage	3.50%
Sublease gross income							$ 300		300
Purchase obligation, purchases during the period						$ 300	0	$ 300	0
Accounts payable, trade										2,100
Percentage of accounts payable trade					92%	92%		92%
Accrued expenses					$ 4,752	$ 4,752		$ 4,752		4,227
Rush License Agreement [Member]
Loss Contingencies [Line Items]
Royalty cost						200	$ 200	400	$ 300
Accrued expenses					1,500	1,500		1,500		$ 1,100
Rush License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty cost		$ 100
Rush License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty cost		$ 100
Letter of Credit [Member]
Loss Contingencies [Line Items]
Security deposit												$ 50		$ 800
Vehicles [Member] | Securities Deposit [Member]
Loss Contingencies [Line Items]
Restricted cash					$ 300	$ 300		$ 300
Building and Building Improvements [Member] | Letter of Credit [Member]
Loss Contingencies [Line Items]
Restricted cash											$ 800
Lease Contract Term One [Member]
Loss Contingencies [Line Items]
Lessee, Operating Lease, Term of Contract				24 months	24 months	24 months		24 months
Lessee operating lease extended lease term				12 months	12 months
Lease Contract Term One [Member] | Vehicles [Member]
Loss Contingencies [Line Items]
Lessee, Operating Lease, Term of Contract													24 months
Lease Contract Term [Member] | Vehicles [Member]
Loss Contingencies [Line Items]
Lessee, Operating Lease, Term of Contract													36 months

Schedule of Warrants (Details)

Schedule of Warrants (Details) - $ / shares	Sep. 27, 2023	Aug. 04, 2023	Jul. 03, 2023	Apr. 05, 2023	Mar. 20, 2023	Feb. 17, 2023	Dec. 21, 2022	Jun. 28, 2022	May 24, 2022	May 04, 2022	Mar. 01, 2022	Jan. 13, 2022	Jun. 09, 2020	Apr. 24, 2020	Jun. 10, 2019	Apr. 11, 2019	May 24, 2018	Jun. 30, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrant or right outstanding																		20,807,539,000
Exercise price																		$ 2.42
Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrant or right outstanding	12,721,893	615,384	349,463	369,231	258,584	130,461	49,227	582,886	894,194	6,666	8,303	8,003	1,092	1,639	1,480	888	451
Exercise price	$ 0.0154	$ 0.0154	$ 0.0154	$ 0.0154	$ 0.0154	$ 0.0154	$ 0.0154	$ 0.0154	$ 0.0154	$ 309.56	$ 897.56	$ 735	$ 0.0154	$ 0.0154	$ 11,962.50	$ 11,962.50	$ 14,062.50
Warrants exercise period	September 27, 2023 to September 27, 2028	August 4, 2023 to August 4, 2028	July 3, 2023 to July 3, 2028	April 5, 2023 to April 5, 2028	March 20, 2023 to March 20, 2028	February 17, 2023 to February 17, 2028	December 21, 2022 to December 21, 2027	May 24, 2022 to June 28, 2027	May 24, 2022 to May 24, 2027	May 4, 2022 to May 4, 2027	March 1, 2022 to March 1, 2027	March 1, 2022 to March 1, 2027	June 9, 2020 to June 9, 2025	April 24, 2020 to April 24, 2025	December 10, 2019 to June 10, 2026	October 11, 2019 to April 11, 2026	May 24, 2018 to May 24 2025
Prefunded Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrant or right outstanding	4,807,694
Exercise price	$ 0.0010
Warrants exercise period	September 27, 2023 to September 27, 2028

Summary of Common Stock Reserve

Summary of Common Stock Reserved for Future Issuance (Details)	Jun. 30, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved upon exercise of stock options outstanding	3,713
Common stock reserved upon exercise of common stock warrants	10,598,201
Common stock reserved for the exercise of purchase rights	741,490,642
Common stock reserved for conversion of convertible notes	155,468,037
Number of shares available for grant	37,770,024
Common stock capital shares reserved for future issuance	945,337,558	[1]
Employee Stock Purchase Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for grant	509
Amended and Restated 2014 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for grant	5,823
Inducement Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for grant	609
[1]The potentially dilutive securities in Note 2 – Summary of Significant Accounting Policies

Convertible and Redeemable Pr_3

Convertible and Redeemable Preferred Stock and Stockholders’ Deficit (Details Narrative) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Aug. 07, 2023 USD ($) $ / shares shares	Sep. 15, 2022 USD ($) shares	Jun. 30, 2022 $ / shares shares	Jun. 30, 2024 USD ($) Integer $ / shares shares	Jun. 30, 2023 Integer	Jun. 30, 2024 USD ($) Integer $ / shares shares	Jun. 30, 2023 Integer shares	Dec. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2024 $ / shares shares	Dec. 21, 2023 shares	Dec. 11, 2023 $ / shares shares	Sep. 14, 2023 shares	Dec. 31, 2022 $ / shares	Dec. 16, 2022 $ / shares shares	May 31, 2022 $ / shares shares	Dec. 15, 2021 $ / shares shares	Apr. 30, 2020 $ / shares shares
Class of Warrant or Right [Line Items]
Warrants exercise price | $ / shares				$ 2.42		$ 2.42
Common stock warrant outstanding															894,194
Common stock, par value | $ / shares				$ 0.0001		$ 0.0001		$ 0.0001					$ 0.0001
Class of warrant or right, number of securities called by warrants or rights				20,807,539,000		20,807,539,000
Common stock shares										9,972,074
Preferred stock, shares authorized				5,000,000		5,000,000		5,000,000								5,000,000
Preferred stock, par value | $ / shares				$ 0.0001		$ 0.0001		$ 0.0001								$ 0.0001
Shares authorized	2,300
Redemption premium percentage	25%
Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock | $								$ 1,800
Warrants to purchase up				10,598,201		10,598,201
Preferred stock, shares issued				0		0		0
Common stock, shares authorized				3,000,000,000		3,000,000,000		3,000,000,000				3,000,000,000
Common stock capital share reserved for future issuance				741,490,642		741,490,642
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount						5,671,114,941	191,005,656
Rights [Member]
Class of Warrant or Right [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount						1,546,948,899	28,783,233
Adjuvant and May 2022 Notes [Member]
Class of Warrant or Right [Line Items]
Aggregate purchase rights		942,080
Purchase rights | $		$ 24,700
Series F-1 [Member]
Class of Warrant or Right [Line Items]
Common stock shares										613
Series E1 Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Preferred stock, shares authorized											95,000
Preferred stock, par value | $ / shares	$ 0.0001										$ 0.0001
Conversion price | $ / shares	$ 0.40								$ 0.0154		$ 0.0635
Debt Conversion, Converted Instrument, Amount | $	$ 1,800
Dividend | $				$ 100		$ 100
Series F1 Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Share conversion price | $ / shares				$ 0.0154		$ 0.0154
Series F-1 Shares [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding				22,280		22,280				22,280
Series F-1 Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase up										9,972,074
Series F-1 Convertible and Redeemable Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Temporary Equity, Shares Outstanding				22,280		22,280		22,280
Preferred stock, convertible shares issuable										21,667
Series D Non-Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Preferred stock, shares authorized														70
Preferred stock, par value | $ / shares														$ 0.0001
Preferred stock voting right power percentage														1%
Preferred stock, shares issued														70
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants exercise price | $ / shares				$ 0.0154		$ 0.0154
Common Stock [Member]
Class of Warrant or Right [Line Items]
Common stock warrant outstanding										9,972,074
Warrants outstanding										613
Common Stock [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants exercise price | $ / shares				0.13		0.13
Common Stock [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants exercise price | $ / shares				$ 1.25		$ 1.25
Preferred Stock [Member] | Series E1 Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Temporary Equity, Shares Outstanding	1,800
Preferred Stock [Member] | Series F-1 Convertible and Redeemable Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Temporary Equity, Shares Outstanding				22,280		22,280		22,280	22,280
Underwritten Public Offering [Member]
Class of Warrant or Right [Line Items]
Number of shares to purchase capital stock															362,640
Warrants exercise price | $ / shares															$ 93.75
IPO [Member]
Class of Warrant or Right [Line Items]
Number of shares to purchase capital stock															205,360
Warrants exercise price | $ / shares															$ 93.63
Baker Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants exercise price | $ / shares				$ 0.0154		$ 0.0154
June 2022 Baker Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares to purchase capital stock			582,886
Warrants exercise price | $ / shares			$ 93.75	$ 0.0154		$ 0.0154
Warrants and rights outstanding, term			5 years												5 years
Common stock, par value | $ / shares			$ 0.0001
June 2022 Baker Warrants [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Beneficial ownership limitation percentage			4.99%
June 2022 Baker Warrants [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Beneficial ownership limitation percentage			19.99%
Baker Bros Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Number of shares to purchase capital stock																	2,732
Warrants exercise price | $ / shares																	$ 4,575
Security Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Number of shares to purchase capital stock				1,152,122		1,152,122
Class of warrant or right, number of securities called by warrants or rights				20,807,539		20,807,539
Security Purchase Agreement [Member] | Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants exercise price | $ / shares				$ 0.0154		$ 0.0154
Security Purchase Agreement [Member] | Common Stock [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or rights				2,615,383		2,615,383
Exchange Agreements [Member]
Class of Warrant or Right [Line Items]
Debt Instrument, Convertible, Number of Equity Instruments | Integer				16,303,657	15,218,227	1,161,636,815	24,966,856
Common stock capital share reserved for future issuance				24,350,000		24,350,000

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expense Related to Stock Options (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 219	$ 268	$ 456	$ 685
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	10	29	26	69
Selling and Marketing Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	24	47	59	104
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 185	$ 192	$ 371	$ 512

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross	0	0	0	0
Employee Benefits and Share-Based Compensation			$ 600,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			1 year 2 months 12 days
Employee Stock [Member] | Employee Stock Purchase Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, purchase price of commonscStock, percent			85%
Employee stock purchase plan maximum stock value available for purchase denominator	$ 25,000		$ 25,000
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 0		$ 0

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ in Thousands						1 Months Ended			3 Months Ended
	Sep. 30, 2024	Aug. 29, 2024	Aug. 09, 2024	Jul. 12, 2024	Nov. 20, 2021	Aug. 31, 2024	Aug. 09, 2024	Jul. 31, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2023	Dec. 21, 2023	May 31, 2022
Subsequent Event [Line Items]
Preferred stock, shares issued									0				0
Shares purchase, aggregate purchase price									$ 68	$ 89	$ 6	$ 180
Net proceeds of preferred shares					$ 50,000
Warrants															894,194
Common Stock [Member]
Subsequent Event [Line Items]
Shares conversion									9,768,291	10,731,443
Shares purchase									24,350,000	17,725,000	673,820	718,704
Shares purchase, aggregate purchase price									$ 2	$ 2
Warrants														9,972,074
Subsequent Event [Member]
Subsequent Event [Line Items]
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued							17,500,000
Subsequent Event [Member] | A&R Merger Agreement [Member]
Subsequent Event [Line Items]
Consideration payment				$ 1,800
Subsequent Event [Member] | A&R Merger Agreement [Member] | Preferred Stock [Member]
Subsequent Event [Line Items]
Warrants				930,336
Exchange of warrants, value				$ 150
Dissenting shares				98
Subsequent Event [Member] | A&R Merger Agreement [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Dissenting shares				4,141,434
Subsequent Event [Member] | Exchange Agreement [Member] | Convertible Note Holders [Member]
Subsequent Event [Line Items]
Shares conversion				88,161
Series F-1 Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares issued									1,000
Series F-1 Preferred Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Purchase price						$ 1,000		$ 1,000
Series F1 Preferred Stock [Member] | Subsequent Event [Member] | A&R Merger Agreement [Member]
Subsequent Event [Line Items]
Shares purchase	1,000	2,000	500	500		500		500
Shares purchase, aggregate purchase price	$ 1,000	$ 2,000	$ 500	$ 500
Net proceeds of preferred shares		$ 20,000